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 Obesity is a strong risk factor for type 2 diabetes and cardiovascular 
disease partly because of the changes that occur in white adipose tissue (WAT) 
during weight gain.  As obesity progresses, WAT expands, becomes 
dysfunctional, and increases its secretion of numerous adipokines, including two 
that will be highlighted in this dissertation, the hormone leptin and the chemokine 
macrophage inflammatory protein-1α (MIP-1α).  Our underlying hypothesis was 
that elevated secretion of leptin and MIP-1α from WAT during obesity would 
influence development of obesity-related atherosclerosis, WAT inflammation, and 
systemic insulin resistance. 
 To test the role of hematopoietic cell leptin receptor (LepR) in aortic root 
lesion formation, we conducted three different bone marrow transplantation 
studies in which bone marrow, with or without LepR, was transplanted into 
lethally irradiated: 1) low density lipoprotein receptor deficient (LDLR-/-) mice with 
moderate hyperleptinemia due to Western Diet (WD) feeding, 2) WD-fed LDLR-/- 
mice with pharmacologically induced hyperleptinemia (daily injection of 125 μg 
leptin), or 3) obese, hyperleptinemic, LepR deficient LDLR-/- (LepRdb/db;LDLR-/-) 
mice.  To test the role of MIP-1α in WAT inflammation, we fed WD to male and 
female MIP-1α deficient (MIP-1α-/-), heterozygous (MIP-1α+/-), and MIP-1α 
sufficient (MIP-1α+/+) mice for 16 weeks to induce obesity and examined their 
WAT.  To identify the effects of hyperlipidemia on the metabolic role of MIP-1α, 
we fed WD to male and female MIP-1α-/-;LDLR-/-, MIP-1α+/-;LDLR-/-, and MIP-
1α+/+;LDLR-/- mice and measured aortic root lesion area and fat mass. 
 Removal of macrophage LepR did not influence atherosclerotic lesion 
formation.  This suggests that non-hematopoietic cells, rather than macrophages, 
are potential mediators of leptin’s effects on aortic root lesion formation.  We also 
demonstrated that although expression of MIP-1α increases as a consequence of 
weight gain this chemokine is not critical for the recruitment of monocytes and T-
lymphocytes to WAT in mice with diet induced obesity.  Furthermore, in the 
presence of hyperlipidemia, the absence of MIP-1α was not sufficient to 
attenuate fat mass gain or atherosclerosis during WD feeding.  Taken together, 
these data demonstrate that although MIP-1α may be involved in WAT growth 
under some circumstances, the metabolic phenotype of MIP-1α-/- mice is similar 
to that of MIP-1α+/+ mice. 
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CHAPTER I 
 
 
INTRODUCTION 
 
 
Prevalence of obesity 
 Obesity (BMI>30 kg/m2) and overweight (BMI>25 kg/m2) are both 
conditions of excess energy storage, the majority of which is stored as 
triglycerides (TGs) in white adipose tissue (WAT).  According to the World Health 
Organization, 1 billion people worldwide are estimated to be overweight, at least 
300 million of whom are obese (109).  In the United States, more than 60% of 
adults are estimated to be overweight or obese (Figure 1.1) (2).  Obesity 
increases the risk for numerous diseases including cardiovascular disease and 
type 2 diabetes.  Being overweight or obese also increases the likelihood of 
having other cardiovascular risk factors such as hypertension and dyslipidemia 
(68), and obesity itself is an independent risk factor for cardiovascular disease 
(CVD) (37, 58, 75).  Obese individuals usually have elevated plasma leptin, 
referred to as hyperleptinemia, which is an additional, independent risk factor for 
CVD (154).    Obesity is also a strong risk factor for type 2 diabetes (1, 10), and 
the prevalence of both obesity and type 2 diabetes has been increasing steadily 
over the past few decades (99).  The reasons for these associations are only 
partially understood, and this dissertation will address some of the factors 
thought to link these conditions with obesity. 
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White adipose tissue (WAT) 
 
Structure and functions of WAT 
 The majority of WAT mass is composed of adipocytes and the rest is 
composed of many other cell types including endothelial cells, erythrocytes, and 
leukocytes such as monocytes, macrophages, T-lymphocytes, neutrophils, and 
B-lymphocytes.  The primary functions of WAT include insulating and cushioning 
internal organs as well as storing energy in the form of TGs.  In addition to these 
functions, WAT has an endocrine role, secreting many different adipokines and 
cytokines into the circulation.  Leptin is a key hormone secreted by WAT that, 
together with gastrointestinal hormones, communicates with the central nervous 
system to regulate food intake (79).  Lipolysis of TGs from adipocytes is also 
highly regulated, such that plasma non-esterified fatty acid levels are controlled 
66.0%
32.3%
1.7%
Overweight & obese
Healthy weight
Underweight
 
 
Figure 1.1.  Prevalence of overweight and obesity in the United States 
based on body mass index.
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during fasting and feeding (174).  A sufficient amount of properly functioning 
WAT is necessary for health.  Lipodystrophy—a pathological condition in which 
WAT mass is insufficient—as well as obesity, are associated with insulin 
resistance and ectopic lipid storage (18).  In this dissertation, we will focus on the 
effects of obesity on WAT. 
 
Pathophysiology of WAT in obesity 
 As obesity progresses, WAT expands and becomes dysfunctional.  
Hypoxia within the rapidly growing tissue, adipocyte cell death, and secretion of 
cytokines by adipocytes, endothelial cells, or resident leukocytes cause both 
paracrine and endocrine effects (143).  Locally, these changes signal for immune 
cells to enter the WAT to clear the debris and resolve the inflammation, however, 
the resulting influx of leukocytes can be detrimental and may interfere with 
adipocytes’ sensitivity to insulin.  WAT mediates its influence over other tissues 
in an endocrine manner also, as seen by elevated circulating leptin and 
decreased release of the insulin-sensitizing hormone adiponectin, and altered 
secretion of other adipokines.  Although WAT has the capacity to expand even 
100-fold in adults, ectopic lipid storage in the liver and skeletal muscle is a 
common feature of excessive weight gain and can disrupt the function of these 
other tissues (82).  In this dissertation, we investigate the local and systemic 
consequences of obesity, focusing on the adipokines leptin and macrophage 
inflammatory protein-1α (MIP-1α), which is a chemotactic cytokine (or 
chemokine).  Our underlying hypothesis is that elevated secretion of leptin 
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(Chapter III) and MIP-1α (Chapters IV and V) from WAT during obesity 
significantly influences development of obesity-related atherosclerosis, WAT 
inflammation, and systemic insulin resistance (Figure 1.2). 
 
 
 
Leptin 
 
Leptin and its receptor 
 Leptin is a 16kD protein secreted by WAT.  In healthy weight humans, 
both free and bound leptin are present in the plasma and total plasma leptin 
averages about 0.1 – 1 nmol/l (~1.6 – 16 ng/ml) (91, 126).  However, in obese 
individuals, the proportion of free leptin increases and total plasma leptin can be 
as high as 5 nmol/l (~80 ng/ml) or greater (91). 
Obesity, WAT Expansion
↑ Plasma leptin ↑ MIP-1α (in WAT)
↑ Macrophages
in artery wall?
Worse
atherosclerosis?
↑ Systemic insulin
resistance?
↑ Secretion of
factors from WAT
↑ Leukocyte
infiltration of tissues
Pathophysiological
consequences of obesity
Chapter III Chapters IV & V
↑ Macrophages & 
T-lymphocytes in WAT?
 
 
Figure 1.2.  Overview of hypotheses tested in dissertation. 
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 Leptin receptor (LepR) has 6 isoforms and exists in a soluble and 
membrane bound state.  Soluble leptin receptor binds to and stabilizes circulating 
leptin.  The membrane bound isoforms differ only in the length of their 
intracellular region, and isoform b (LepRb), unlike the other isoforms, has a 302-
amino acid long cytosolic region capable of intracellular signaling.  Leptin 
receptor has been detected on many cell types, but its function is best 
understood on neurons of the arcuate nucleus of the hypothalamus.  Two sets of 
LepRb containing neurons are present within the arcuate nucleus—those that 
synthesize neuropeptide Y (NPY) and agouti related protein (AgRP) and those 
that express proopiomelanocortin (POMC), which is cleaved to form α-
melanocyte stimulating hormone (α-MSH) (103). These function together in a 
feedback loop to regulate energy homeostasis.  Leptin excites POMC neurons, 
which secrete α-MSH, an anorexic (appetite suppressing) factor, and leptin 
inhibits NPY/AgRP neurons, decreasing their secretion of the orexigenic 
(appetite stimulating) factors NPY and AgRP.  Obese individuals lose sensitivity 
to leptin or become “leptin resistant”, as described below. 
 
History of leptin 
 In the 1950s and ‘60s, two spontaneously generated mouse mutations 
with similar obese phenotypes were discovered (59, 60).  Based on parabiosis 
experiments in the 1970s (24, 25), mice with one of the mutations (later identified 
as Lepob/ob mice) were proposed to lack a soluble satiety factor and mice with the 
other mutation (LepRdb/db mice) to lack its receptor.  In 1994, the gene obese was 
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cloned and its sequence suggested that it encoded a secreted factor, which was 
named leptin after the Greek word leptos meaning thin (172).  Its receptor was 
identified and cloned shortly after (144).  LepRdb/db mice have a mutation in their 
leptin receptor and a nearly identical phenotype to Lepob/ob mice with the 
exception of their exceedingly high plasma leptin concentrations. 
 The cloning of leptin initially generated much excitement because injection 
of leptin into Lepob/ob mice induced dramatic weight loss (16, 50, 116).  
Researchers hoped leptin could be used to pharmacologically treat obese 
individuals; however, most humans are hyperleptinemic rather than leptin 
deficient, and the potential therapeutic uses of leptin are being reconsidered.  
Many clinical uses of leptin target thin, rather than obese, individuals.  Humans in 
a state of negative energy balance—such as those with anorexia nervosa or 
highly training women athletes—can experience amenorrhea, compromised 
immunity, and other health deficiencies because of insufficient leptin levels.  
Therefore, clinical trials are underway to test the effectiveness of therapeutic 
leptin interventions (7).  Centrally administered leptin has also been suggested 
as a therapy for diabetes because leptin can regulate β-cell secretion of insulin 
and glucose metabolism (64).  It is critical to determine leptin’s roles in CVD, not 
only for appropriate care of patients with CVD but also to understand the 
consequences of its various clinical uses. 
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Leptin resistance 
 Healthy, lean individuals can respond properly to leptin’s appetite 
suppressing effects, but obese individuals lose sensitivity to the anorexic effects 
of leptin, becoming “leptin resistant”.  This term has been used to refer to a range 
of concepts, but one of the main mechanisms by which leptin resistance occurs 
is cellular resistance in the arcuate nucleus of the hypothalamus.  Upon leptin 
binding to homodimerized LepRb, tyrosine kinase Jak2 associates with LepR and 
phosphorylates tyrosines 985, 1077, and 1138.  Phosphorylation of Y985 
attenuates leptin signaling as part of a negative feedback loop.  Amplification of 
this feedback or removal of LepR from the plasma membrane can mediate 
cellular resistance in obese individuals (103).  Leptin has pleiotropic effects, not 
all of which are inhibited in obese individuals.  Selective leptin resistance is 
defined as resistance to the anorexic effects of leptin while retaining the 
response to leptin’s other effects.  For example, elevated stimulation of 
sympathetic nerve activity by hyperleptinemia is thought to aggravate 
hypertension in obese individuals (94).  The hypothesis we test in Chapter III is 
based on the concept of selective leptin resistance since we propose that 
macrophages retain responsiveness to leptin despite resistance to leptin at the 
level of the hypothalamus. 
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Atherosclerosis 
 Atherosclerosis is a chronic inflammatory disease in which lipids 
accumulate within the intima of the artery wall and form a lesion or plaque.  Many 
cell types participate in the development of atherosclerotic lesions including 
various subsets of monocytes/macrophages and T-lymphocytes, neutrophils, 
mast cells, B-lymphocytes, and progenitor cells (157), although in this 
dissertation we will focus on the role of monocytes/macrophages.  Formation of 
atherosclerotic lesions can lead to hazardous consequences incuding myocardial 
infarction and stroke (Figure 1.3) (86).    
 Progression of atherosclerosis is strongly associated with 
hypercholesterolemia and is also associated with hypertriglyceridemia, although 
elevated plasma TGs alone is usually insufficient to drive the disease (41).  An 
extreme illustration of the association between hypercholesterolemia and 
atherosclerosis is homozygous familial hypercholesterolemia (HFHC), caused by 
a genetic mutation in the low density lipoprotein receptor (LDLR) gene.  HFHC 
causes extremely high plasma LDL cholesterol concentrations and severe 
atherosclerosis before age 10 (93).  
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 The initiator of “fatty streaks” or early atherosclerotic lesions is not fully 
understood but involves endothelial cell dysfunction—often under conditions of 
hyperlipidemia—as well as inflammation.  Endothelial cell injury can increase the 
adhesion of leukocytes and activated platelets to the endothelium and increases 
its permeability to lipids (157).  Monocyte infiltration into the lesion may occur 
because of their increased adherence to endothelial cells as well as in response 
to lipid accumulation, and it is also an early step in lesion formation.  As shown in 
Figure 1.4, circulating monocytes attach to various cell adhesion molecules, roll 
along the endothelium, firmly attach via integrin binding, and then diapadese 
 
 
Figure 1.3.  Schematic of the life history of an atheroma.  Progression 
from a healthy artery to an atheroma and the different fates of the plaque 
including rupture, thrombosis, and the resultant myocaridial infarction.  From 
Libby P, Nature. 2002 Dec 19-26;420(6917):868-74.  For a detailed 
description of figure please see the original review. 
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through the endothelial cell layer and into the artery wall.  After exiting the 
circulation, these monocytes differentiate into macrophages and phagocytose 
lipids through their scavenger receptors.  These macrophages become “foam 
cells”, so named because their high lipid content (which is mainly composed of 
cholesterol) gives them a foamy appearance.  The macrophages within the 
nascent plaque secrete reactive oxygen species and matrix metalloproteinases, 
as well as proinflammatory cytokines, which recruit more leukocytes to the site of 
inflammation in the artery wall.  In Chapter III, we will investigate whether leptin 
signaling through macrophage LepRb is involved in atherosclerotic lesion 
development. 
 
 
 
 
Figure 1.4.  Recruitment of monocytes to artery wall and their 
differentiation into macrophages.  Figure is from Libby P, Nature. 2002 Dec 
19-26;420(6917):868-74.  Please see reference for detailed description of 
figure. 
 11 
Mouse models of atherosclerosis 
 Wild type C57BL/6 mice normally clear LDL and VLDL efficiently and, 
consequently, even when fed a high cholesterol diet such as the Western Diet 
(WD, see Chapter II for details) they develop virtually no atherosclerotic lesions.  
Thus, the most common mouse models of atherosclerosis are mice with 
mutations in the main lipoprotein clearance pathway.  Apolipoprotein E deficient 
(apoE-/-) mice do not produce apoE (117), a protein which is normally packaged 
with lipids to aid in their clearance from the plasma.  apoE preferentially binds 
LDL receptors to clear chylomicron remnants and very low density lipoprotein 
(VLDL) but is also a ligand for LDL receptor-related protein (LRP).  apoE-/- mice 
have hypercholesterolemia and develop atherosclerotic lesions spontaneously, 
even when fed a chow diet (171).  Mice lacking LDL receptor (LDLR-/-) are also a 
commonly used model of atherosclerosis.  Chow diet fed LDLR-/- mice have a 
much greater amount of circulating LDL and VLDL so that their lipoprotein profile 
resembles that of humans (see Figure 1.5).  When fed WD, LDLR-/- mice become 
severely hypercholesterolemic (62) and begin to develop arterial plaques.  We 
will use the WD-fed LDLR-/- mouse model throughout this dissertation. 
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Monocytes and macrophages 
 In adult mammals, hematopoietic stem cells reside in the bone marrow 
where they regenerate themselves and produce cells which differentiate into 
various myeloid and lymphoid progenitor cells.  Downstream of common myeloid 
progenitor cells are erythrocytes and numerous leukocytes including monocytes, 
which can differentiate into macrophages once they have exited the circulation to 
enter a tissue (Figure 1.6).  Macrophages are antigen presenting cells and are 
part of the innate immune system.  Expression of cell surface markers is used to 
identify macrophages and classify them into subgroups.  F4/80 and CD68 are 
both cell surface glycoproteins which are commonly used to identify macrophage 
populations and are more specific for macrophages than other markers such as 
CD11b (Mac1) (87). 
 Like T-lymphocytes, macrophages are now understood to be a 
heterogeneous population of cells that can be polarized toward an M1 “classically 
activated” or an M2 “alternatively activated” phenotype (reviewed in (46, 92)).  
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Figure 1.5.  Cholesterol fractionation by FPLC in human and mouse 
plasma. 
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The M1 macrophage phenotype is induced by inflammatory stimuli and results in 
secretion of pro-inflammatory cytokines, whereas the M2 phenotype is induced 
by exposure to IL-4 and IL-13 and results in the secretion of anti-inflammatory 
cytokines.  One hallmark feature of M2 macrophages is the production of 
arginase, which blocks iNOS activity and may allow M2 macrophages to 
contribute to tissue repair (133). 
 
 
Figure 1.6.  Haematopoietic hierarchy.  Figure shows the generation of 
blood and immune cells from the HSCs.  BFU: Blast-forming unit; CFU: 
Colony-forming unit; CLP: Common lymphoid progenitor; CMP: Common 
myeloid progenitor; GEMM: granulocyte/erythrocyte/monocyte/ 
megakaryocyte; GM: Granulocyte-macrophage; HSC:Haematopoietic stem 
cell.  Figure and legend text from Ramkissoon SH et al. Expert Opin. Biol. 
Ther. (2006) 6(2):109-120. 
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WAT inflammation in obese individuals and subsequent insulin resistance 
 WAT is an insulin responsive tissue.  Insulin both inhibits lipolysis and 
promotes the delivery of glucose to adipocytes via the glucose transporter 
GLUT4.  In insulin resistant individuals, elevated secretion of insulin by the 
pancreas can overcome insulin resistance to maintain relatively normal blood 
glucose concentrations; however, elevated secretion of insulin does not prevent 
the increased flux of NEFAs into and out of WAT that is observed in obese 
individuals (135).  During obesity, disruption of WAT’s sensitivity to insulin can 
lead to uncontrolled release of non-esterified fatty acids (NEFAs).  This increases 
the liver, pancreas, and skeletal muscle’s exposure to NEFAs and provides more 
substrate for liver VLDL synthesis (135).  Therefore, insulin resistance in WAT 
can lead to lipid deposition in other tissues as well as systemic insulin resistance.  
ATMs and T-lymphocytes present in WAT contribute to the dysfunction of 
adipocytes during obesity, and subsequently, to insulin resistance, as described 
below. 
 
Monocyte recruitment to WAT 
 Monocyte recruitment into WAT is an area of intense investigation (49, 65, 
67, 70, 131, 147, 158).  Macrophage accumulation in WAT correlates positively 
with obesity, as measured by BMI and adipocyte size (159) and is increased in 
obesity in both humans and rodents (166).  Microarray analysis of perigonadal 
WAT from multiple models of obese mice was used to identify genes correlated 
with obesity, and 30% of the 100 most significant positively correlated genes 
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were macrophage associated genes (159).  Within WAT, macrophages surround 
dead adipocytes in “crown-like structures” (22, 101, 140), which stain positive for 
F4/80, MAC-2, TNF-α, and IL-6—indicative of their macrophage content and 
inflammatory properties (22, 101, 140).  The macrophages in the crown-like 
structures are indeed recruited to the WAT.  It has been shown that during the 
development of obesity in mice, monocytes exit the bone marrow and enter the 
circulation (159), from which they enter the WAT and differentiate into pro-
inflammatory (M1) macrophages (89).  Resident alternatively activated (M2) 
macrophages are retained in the WAT but do not collect around the dead 
adipocytes. 
 ATMs have been proposed to contribute to whole body insulin resistance 
by inducing inflammation and local insulin resistance.  Xu et al. demonstrated 
that in mice with diet induced obesity (DIO), macrophage accumulation 
temporally precedes an increase in circulating insulin levels (166), and treatment 
with the insulin-sensitizing drug rosiglitazone decreases the expression of 
macrophage-originated genes in visceral fat (166).  This paracrine effect between 
macrophages and adipocytes is thought to be partially mediated by TNFα and IL-
6.  Mice with an absence of macrophage-derived TNFα exhibit reduced 
epididymal fat pad weight and enhanced insulin sensitivity in comparison to 
control mice (35).  Using in vitro studies, Suganami et al. showed that 
macrophage secreted TNFα induces lipolysis and inhibits adipocyte insulin 
signaling via serine phosphorylation of insulin receptor substrate-1 (IRS-1) (141).  
TNFα’s induction of lipolysis causes increased NEFA release by adipocytes, 
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which further exacerbates the inflammatory phenotype of the macrophages, 
creating a vicious cycle of inflammation and insulin resistance (141).  Thus, it is 
widely believed that macrophage infiltration into WAT leads to increased local 
inflammation, which in turn reduces insulin sensitivity both in the WAT and 
systemically.  
 
T-lymphocyte populations in WAT 
 T-lymphocytes are recruited to WAT within 2 weeks of high fat diet feeding 
in mice (105), and numerous groups are currently investigating their role in WAT 
inflammation and insulin resistance (39, 72, 105, 124, 162, 164).  In vitro 
migration experiments support the idea that adipocyte-secreted chemokine 
RANTES is involved in T-lymphocyte recruitment to the WAT (164), and the 
arrival of neutrophils in WAT within the first week of high fat diet feeding suggests 
that they, too, may be involved in initiating the recruitment of other leukocytes 
(38). 
 T-lymphocytes can be characterized according to their cell surface 
markers.  Cytotoxic CD3+/CD8+/CD4- T-lymphocytes are increased in the WAT 
of both DIO and Lepob/ob mice (105, 124).  In contrast, CD3+/CD8-/CD4+ T-
lymphocytes and Foxp3+ T-regulatory (Treg) lymphocytes are decreased in the 
WAT of obese mice in comparison to WAT from lean mice (39, 105).  Treg 
lymphocytes are also less frequent in visceral WAT from obese versus lean 
humans (162), but in regard to CD4+ and CD8+ T-lymphocytes the data from 
humans and mice are not yet reconciled.  In patients with type 2 diabetes, 
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Kintscher et al. detected only moderate expression of CD8 in WAT, but 
demonstrated the presence of CD4+ T-lymphocytes and a positive correlation 
between CD4 expression and body weight (72).  Kintscher et al. also 
demonstrated that the majority of the ATMs were HLA-DR-positive, suggesting 
that they may have been activated by interferon-γ, a cytokine released by CD4+ 
helper T-lymphocytes (72).  These variances might be due to species 
differences; however, the interaction of inflammatory cells within WAT is 
dynamic, and perhaps the CD8+ T-lymphocytes are common during the early 
stages of human obesity. 
 Macrophage infiltration of the WAT has been shown to temporally precede 
systemic insulin resistance in mice with DIO (166), but the converse has also 
been demonstrated.  T-lymphocyte accumulation in WAT, as well as impaired 
glucose tolerance and insulin sensitivity can occur before macrophage 
accumulation in mice with DIO (72).  Thus, the sequence in which immune cells 
infiltrate WAT and the sequence of events leading to insulin resistance in 
humans is not yet clearly defined.  In Chapters IV and V, we investigate the role 
of MIP-1α, a chemoattractant for both T-lymphocytes and monocytes, in obesity-
related WAT inflammation.  This dissertation will conclude with a discussion of 
the timeline of the events in obesity-related WAT inflammation (Chapter VI). 
 
Initiation of leukocyte recruitment to WAT during weight gain 
 Both adipocyte hyperplasia and hypertrophy can contribute to WAT 
expansion; however, in adults, hypertrophy appears to predominate.  Some of 
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the consequences of hypertrophy include increased fatty acid flux from 
adipocytes, increased leptin secretion, hypoxia, and adipocyte death.  These 
adipocyte-related consequences of WAT expansion are all possible contributors 
to the initiation of monocyte and T-lymphocyte recruitment.  Here we will highlight 
hypoxia and adipocyte death, two of the top candidates for initiation of leukocyte 
recruitment to WAT during obesity, as well as the potential role of leptin.  Lastly, 
we will discuss models in which the correlation between WAT growth and 
leukocyte infiltration seems to be dissociated. 
 
Hypoxia 
 At least three different obese mouse models (DIO, KKAy, and Lepob/ob) 
have been used to demonstrate that hypoxia is present in obese WAT (54, 167).  
Decreased vascular density, which has been observed in obese mice (112, 153), 
may contribute to this.  Furthermore, protein and mRNA levels of hypoxia-
inducible factor-1α (HIF-1α) are elevated in WAT from obese mice, as are mRNA 
levels for other hypoxia inducible genes (54, 167).  Evidence suggests that 
hypoxia may initiate an inflammatory response as in vitro exposure of primary 
adipocytes and macrophages to hypoxia increases their expression of multiple 
inflammatory genes (167).   
Human adipocytes, like murine adipocytes, also have increased 
expression of HIF-1α and other hypoxia related genes when exposed to low 
oxygen levels (1%) (156).  Human preadipocytes exposed to hypoxia had 
elevated HIF-1α mRNA, increased secretion of vascular endothelial growth 
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factor, and although leptin expression and secretion was nearly absent in 
preadipocytes under normal oxygen conditions, hypoxia stimulated their 
expression and secretion of leptin (155).  Therefore, hypoxia is potentially 
involved in several of the initiating factors of macrophage recruitment including 
leptin secretion and adipocyte death (discussed below), as well as an initial 
upregulation of inflammatory genes.   
 
Adipocyte death 
 Adipocyte death does occur in WAT from lean individuals, but its 
frequency increases with obesity and it positively correlates with adipocyte 
hypertrophy (22, 101, 118, 140).  Therefore, it is believed that the influx of 
macrophages to the WAT is partially in response to adipocyte death and the 
need for these dying cells to be phagocytosed.  Support for this comes from 
hormone sensitive lipase deficient mice, which have hypertrophic adipocytes and 
increased adipocyte cell death despite their being lean (110).  Epididymal and 
visceral WAT contain more dead adipocytes and inflammation as well as a 
greater accumulation of ATMs than subcutaneous WAT (14, 100, 101, 108, 140).  
Thus, it is likely that adipocyte cell death, which may be caused by the hypoxic 
conditions that occur during rapid tissue expansion (reviewed in (45)), is a signal 
that attracts phagocytic macrophages. 
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Leptin’s potential roles in WAT inflammation 
 Leptin, which like IL-6 is a class-I cytokine, is a chemoattractant for 
multiple cell types.  We have shown in vitro that leptin can induce monocyte 
migration (47).  In addition, leptin negatively regulates the proliferation of Treg 
lymphocytes (34), which are much more abundant in lean than in obese 
individuals.  Therefore, this evidence suggests that leptin can both actively recruit 
new monocytes to WAT while at the same time inhibiting the proliferation of Treg 
lymphocytes, which suppress WAT inflammation. 
 
Correlation between WAT mass and inflammation 
 Although expansion of WAT is typically associated with an increased 
accumulation of inflammatory leukocytes, situations in which these two 
parameters are disconnected can provide insight into the commonly observed 
correlation between obesity and leukocyte accumulation within WAT.  Two recent 
publications have examined the effect of the PPARγ agonists thiazolidinediones 
(TZDs) on WAT and insulin sensitivity (78, 136).  TZD administration increases 
insulin sensitivity in people with type 2 diabetes but simultaneously causes 
weight gain and increases the size of subcutaneous adipocytes (40, 78).  In 
addition, patients who become more insulin sensitive in response to TZDs have 
increased intramyocellular adipocytes and fewer inflammatory macrophages 
within their WAT (136).  These data suggest that treatment with TZDs increases 
the capacity for healthy storage of TGs and that WAT inflammation—not merely 
the presence of more or larger adipocytes—is responsible for obesity-associated 
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insulin resistance.  Similarly, fish oil supplementation in high fat diet fed mice 
increases WAT mass but decreases macrophage infiltration and inflammation in 
the WAT, and this is associated with increased insulin sensitivity (131).   
 Collagen VI knockout mice demonstrate another facet to the relationship 
between adipocyte size and insulin sensitivity.  Within WAT, the extracellular 
matrix usually becomes denser during obesity, and collagen VI is one of the main 
components of this matrix.  In the absence of collagen VI, individual adipocyte 
growth is uninhibited, and, in this context, larger adipocytes are associated with 
reduced WAT inflammation and increased systemic insulin sensitivity (69).   
 As another example, individuals with lipodystrophy—like many obese 
individuals—are insulin resistant and have increased WAT inflammation (18, 
137).  Thus, in this example as well as the previous, WAT inflammation and 
insulin resistance are positively correlated, and proper functioning of adipocytes 
is more important than their size.  The amount of adiponectin secreted appears 
to be an important factor in this relationship.  In fish oil-fed mice and in TZD-
treated patients secretion of more adiponectin—even if by larger adipocytes—is 
associated with an improvement in insulin sensitivity and reduced WAT 
inflammation (131).  In agreement with this, adiponectin transgenic mice have 
improved insulin sensitivity and less WAT macrophage infiltration even though 
their adipocytes are smaller than those of wild type mice, indicating once again 
that adipocyte function and the adipokines secreted are more important than cell 
size.  
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Chemokines as propagators of WAT inflammation 
 Similar to how chemokines direct leukocytes into the artery wall in 
atherosclerosis, evidence suggests that they also propagate inflammation in 
WAT (Figure 1.7).   Initial reports indicated that the chemokines MIP-1α and 
MCP-1 as well as the inflammatory cytokine TNFα were mainly derived from 
stromal vascular cells rather than adipocytes (14, 159, 166).  However, other 
reports have indicated that adipocytes, not stromal vascular cells, secrete more 
chemokines during weight gain (63, 84) and that 3T3-L1 adipocytes increase 
secretion of chemokines in response to free fatty acid administration (63).  
Therefore, both adipocytes and leukocytes appear to produce chemokines in 
WAT and the proportion of inflammatory mediators being produced by each likely 
changes during the development of obesity.  Evidence for the importance of 
chemokines in WAT inflammation in obese mice and humans is discussed below.  
 
The role of chemokines in WAT inflammation: Mouse studies 
 Numerous chemokines exhibit elevated mRNA and protein levels in the 
WAT and plasma of mice with genetic or diet-induced obesity.  Expression of 
macrophage chemokines monocyte chemotactic protein-1 (MCP-1) and MIP-1α 
are increased in the WAT of LepRdb/db, Lepob/ob, and diet induced obese mice (19, 
61, 65, 66, 104, 166, 168).  Other chemokines upregulated in WAT from diet 
induced obese and/or Lepob/ob mice are MCP-2 (158), MCP-3 (158), RANTES 
(164), and CXCL14 (104). Receptors for these chemokines such as CCR2, 
CCR3, and CCR5 are also elevated in the WAT of mice with DIO (158, 164). 
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Furthermore, in comparison with WAT from lean mice, epididymal and inguinal 
WAT from diet induced obese mice have altered gene expression of 60 
inflammatory genes, including MCP-1 and MCP-3, which were the two most 
highly upregulated inflammatory genes (19). 
 It is clear that obese mice have elevated chemokines in their WAT.  
However, some of their functions may overlap, such that alteration of only one 
chemokine or chemokine receptor at a time may have only minor effects on ATM 
accumulation (143).  More work needs to be done to clarify which chemokines 
are important in the recruitment of macrophages and the mechanisms by which 
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Figure 1.7. Recruitment of macrophages to tissues in response to 
inflammatory signal.  This process is well-documented in the recruitment of 
leukocytes to the artery wall and is a model for what is thought to occur in 
WAT.  Monocytes and macrophages are shown above, but the process for 
other leukocytes is similar.  Adapted from Luster AD,  
N Engl J Med. 1998 Feb 12;338(7):436-45.  
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they induce insulin resistance.  In Chapter IV we investigate the role of MIP-1α in 
recruitment of leukocytes to WAT. 
 
The role of chemokines in WAT inflammation: Human studies 
 Multiple human studies have demonstrated an elevation in gene 
expression of various chemokines in WAT in obesity, including MCP-1, MIP-1α, 
MIP-1β, MCP-2, MCP-4, MIP-2α, and pulmonary and activation-regulated 
chemokine (PARC) (14, 31, 102, 160).  Insulin resistant humans have increased 
expression of macrophage markers in WAT in comparison to insulin sensitive 
individuals, and WAT expression of MIP-1α and MCP-1 is elevated during 
hyperinsulinemic euglycemic clamps in people with insulin resistance (160).  
Furthermore, a significant positive correlation has been observed between WAT 
gene expression of the chemokines MIP-1α, MCP-1, and MCP-2 and fasting 
serum insulin as well as whole body glucose disposal rate (102).  Finally, in a 
comparison of obese versus lean individuals, expression of 6 different 
chemokines and their receptors was higher in obese humans, and the expression 
of MIP-1α and RANTES positively correlated with fasting plasma insulin levels 
independent of waist circumference (56). Thus, analysis of human WAT has 
demonstrated a potential role for chemokines, including MIP-1α, in the 
propagation of macrophage recruitment and in obesity-related insulin resistance. 
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Macrophage inflammatory protein-1α (MIP-1α) 
 MIP-1α is a classic chemokine of 69 amino acids in length in its mature 
state.  It is a member of the CC chemokine family, named so because of their 
two sequential cysteine residues near the N-terminus.  In mice, standard 
nomenclature for MIP-1α is CC chemokine ligand 3, or CCL3.  In humans, MIP-
1α is encoded by two genes: CCL3 and CCL3L (115).  Although MIP-1α can be 
expressed in adipocytes, platelets, osteoblasts, astrocytes, and epithelial cells, 
mature hematopoietic cells tend to be its major source.  Bacterial 
lipopolysaccharide, viral infection, TNFα and other pro-inflammatory cytokines 
induce MIP-1α expression (44, 96). Our laboratory has also shown that its 
expression in macrophages is greatly increased upon exposure to human very 
low density lipoprotein (Figure 1.8) (132). MIP-1α signals through the G protein 
coupled CC chemokine receptors CCR1, CCR3, and CCR5 (98).  MIP-1α has 
been shown to induce the chemotaxis of monocytes (150), activated T-
lymphocytes (especially CD8+ cells), B-lymphocytes, NK cells, basophils, and 
eosinophils (6, 30, 128, 134, 145, 146, 148).  Expression of MIP-1α and its 
receptors is upregulated in the WAT of obese humans and rodents (see below 
for more details) (57, 63, 84, 166).  The importance MIP-1α in the recruitment of 
leukocytes to WAT in obese mice will be addressed in Chapters IV and V. 
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The role of chemokines and chemokine receptors in CVD 
 
Predictive and diagnostic potential of chemokine levels for CVD 
 Several chemokines are significantly elevated in the circulation of 
individuals with coronary artery disease (CAD), and although increased 
inflammation is not unique to atherosclerosis, a recent publication suggests 
 
 
Figure 1.8.  Dose- and time-dependent effects of VLDL on MIP-1α 
expression in mouse peritoneal macrophages.  A, B: Mouse primary 
peritoneal macrophages were incubated with 0, 50, 100, or 150 mg/ml VLDL 
for 6 h.  RNA was isolated, and MIP-1α gene expression was measured by 
RT-PCR.  Β-Actin was used as a control to confirm equal RNA concentrations.  
A: Representative amplification of duplicate samples. B: Band intensities from 
six samples were quantified using Quantity One software and plotted as 
means 6 SEM.  C, D: Mouse primary peritoneal macrophages were incubated 
with 100 mg/ml VLDL for 0, 2, 4, 6, or 24 h. C: RNA was isolated from cells 
and analyzed for MIP-1α expression by RT-PCR. D: Band intensities from six 
samples were quantified using Quantity One software and plotted as means ± 
SEM. *p<0.01 compared with 0 mg/ml VLDL; **p<0.001 compared with 0 and 
50 mg/ml VLDL. Figure and legend text from Saraswathi and Hasty.  J Lipid 
Res. 2006 Jul;47(7):1406-15. Epub 2006 Apr 25.  
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measurement of a combination of chemokines can be helpful for predicting 
disease.  Inclusion of circulating CXCL10, MIP-1α, and CCL7 with the traditional 
risk factors of waist circumference and smoking in a linear regression model has 
better diagnostic potential than linear regression models based only on traditional 
risk factors (3).  In patients with unstable angina pectoris, circulating MIP-1α, 
RANTES, and CCL18 transiently increase during ischemia, and plasma MIP-1α 
is a potential predictor of future ischemic events (32, 80).  Plasma MIP-1α as well 
as MCP-1 and RANTES are also elevated in patients with severe acute 
myocardial infarction (77, 113).   These and other clinical studies demonstrate 
that measurement of circulating chemokines such as MIP-1α may assist in early 
detection of CVD and improve patient care. 
 Secretion of chemokines by peripheral blood mononuclear cells (PBMCs) 
is altered by some CVDs.  PBMCs from CAD patients spontaneously secrete 
more MCP-1, IL-8, GROα, CXCL9, and CXCL10 than PBMCs from controls, and 
they release greater amounts of MCP-1 and IL-8 when stimulated with oxLDL 
relative to controls (13, 33).  Unstimulated PBMCs from hypercholesterolemic 
HFHC patients release more MIP-1α, MIP-1β, and IL-8 than control PBMCs, and 
this spontaneous release is positively correlated with plasma total and LDL 
cholesterol (53).  MIP-1α, MIP-1β, and IL-8 may be especially important 
mediators of inflammation in individuals with high LDL cholesterol.  As shown in 
Chapter V, we measured atherosclerotic lesion area and determined the 
consequences of MIP-1α deficiency in LDLR-/- mice to test the combined 
importance of MIP-1α and hyperlipidemia. 
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Chemokine receptors CCR5 and CCR1 and atherosclerosis 
 Several studies have investigated the roles of CCR5 and CCR1, receptors 
for MIP-1α, macrophage inflammatory protein-1β (MIP-1β/CCL4) and RANTES.  
CCR5 deficiency reduces atherosclerotic lesion area and inflammation in both 
apoE-/- and LDLR-/- mice (12, 120, 121), although CCR5 deficiency is not 
protective during early atherosclerosis in apoE-/- mice (81).  Furthermore, CCR5 
deficiency protects against neointima formation induced by arterial wire injury in 
apoE-/- mice (169).  Some of these beneficial effects can be accounted for by the 
upregulation of anti-inflammatory cytokine IL-10 in CCR5-/- mice (12, 169).  The 
atherogenic effects of CCR5 appear to be independent of the well-studied 
chemokine MCP-1 and the chemokine receptor CX3CR1, since CCR5 
antagonism further decreases lesion area in apoE-/- mice that are also deficient in 
MCP-1 and CX3CR1 (apoE-/-;MCP-1-/-;CX3CR1-/- mice) (26).  In contrast to 
CCR5, CCR1 deficiency increases lesion area in atherosclerosis prone mice (12, 
119), suggesting that CCR1 is protective against lesion formation.  In Chapter V 
we examine the role of MIP-1α, a CCR5/CCR1 ligand, in atherosclerotic lesion 
formation. 
 
Significance 
 Approximately two-thirds of American adults are overweight or obese (2).  
Obesity is recognized as a strong risk factor for CVD and type 2 diabetes, 
partially because of altered release of various hormones and cytokines from 
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WAT.  The potential role of these secreted factors in the health conditions 
associated with obesity has only begun to be addressed.   The following chapters 
will describe our research regarding how leptin/LepRb signaling in macrophages 
influences atherosclerosis (Chapter III) and the role of MIP-1α in diet-induced 
obesity, WAT inflammation, and systemic insulin resistance (Chapters IV and V, 
see Figure 1.2).  Understanding the roles of leptin and MIP-1α in obesity will 
potentially enhance clinicians’ ability to assist patients with obesity, 
hyperlipidemia, and CVD.   
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
 
Mouse care 
 
Ethics Statement 
 All procedures were performed according to and with approval by 
Vanderbilt University’s Institutional Animal Care and Use Committee. 
 
Diets 
 Mice were fed a standard rodent chow diet (LabDiet 5001; 12% kcal from 
fat, 28% kcal from protein, 60% kcal from carbohydrates) unless otherwise 
indicated.  Western Diet (WD; TD.88137, Harlan Teklad; Madison, WI) is 
composed of 42% kcal from fat, 15% kcal from protein, and 43% kcal from 
carbohydrates with 0.15% added cholesterol. 
  
Mice used in Chapter III 
 All mice were originally purchased from Jackson Laboratories (Bar Harbor, 
ME) and were on the C57BL/6 background.  Donor and recipient mice for all 
experiments were LDL receptor deficient (LDLR-/-, strain B6.129S7-Ldlr tm1Her/J).  
LDLR-/- mice heterozygous for LepR deficiency were crossed to generate 
homozygous LepRdb/db;LDLR-/- mice.  
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Mice used in Chapter IV 
 MIP-1α deficient (MIP-1α-/-) mice on a C57BL/6 background were 
purchased from Jackson Laboratory (strain B6.129P2-Ccl3tm1Unc/J) and crossed 
with C57BL/6 mice from our colony (originally purchased from Jackson 
Laboratory) to obtain MIP-1α+/- mice.  Mice from this F1 generation were bred to 
yield MIP-1α+/+, MIP-1α+/-, and MIP-1α-/- littermates, and the colony was 
maintained by breeding MIP-1α heterozygous mice.  We obtained female mice at 
the expected Mendelian ratio (24% MIP-1α+/+, 49% MIP-1α+/-, and 27% MIP-1α-/-, 
n=119), in agreement with the publication in which these mice are first described 
(29).  However, we obtained fewer MIP-1α+/+ male littermates than predicted 
(17% MIP-1α+/+, 57% MIP-1α+/-, and 26% MIP-1α-/-, n=132). 
 At 8 wks of age, male and female littermates were switched from CD to 
WD, which they were fed for a total of 16 wks.  A second cohort of mice was kept 
on chow diet throughout the duration of the study.  In both the WD- and CD-fed 
groups, mice were weighed weekly for a 16 wk period and were bled at 24 wks of 
age.  Their total lean and fat mass was measured every 4 wks, from wks 8 to 24 
using nuclear magnetic resonance (NMR) with a Bruker Minispec (Woodlands, 
TX) housed in Vanderbilt University’s Mouse Metabolic Phenotyping Center 
(MMPC).   
 Mice were genotyped using DNA extracted from ear tissue.  The PCR 
protocol was obtained from Jackson Laboratory’s website, and the following 
primers were used: 5’–ctt ggg tgg aga ggc tat tc–3’ (mutant forward), 5’–agg tga 
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gat gac agg aga tc–3’ (mutant reverse), 5’–atg aag gtc tcc acc act gc–3’ (wild 
type forward), and 5’–agt caa cga tga att ggc g–3’ (wild type reverse). 
 
Mice used in Chapter V 
 LDLR-/- and MIP-1α-/- mice were originally purchased from Jackson 
Laboratories and were propagated within our colony.  We crossed MIP-1α-/- and 
LDLR-/- mice to generate MIP-1α+/-;LDLR+/- mice, which we bred to generate 
littermate MIP-1α+/+;LDLR-/-, MIP-1α+/-;LDLR-/-, and MIP-1α-/-;LDLR-/- mice.   
 
Genotyping protocol (Chapter V) 
 To genotype the mice used Chapter V, we chose primer pairs that allowed 
us to discriminate between mutations in the LDLR and MIP-1α genes, which both 
contained inserted neo cassettes.  To determine the LDLR genotype, we used 3 
primer sequences from Jackson Labs’ website: 5'-AAT CCA TCT TgT TCA ATg 
gCC gAT C-3' (within the neo region), 5’-CCA TAT gCA TCC CCA gTC TT-3’ 
(primer common to wild type and mutant mice), and 5’-gCg ATg gAT ACA CTC 
ACT gC-3’ (within exon 4, only present in wild type mice).  The MIP-1α genotype 
was determined according to the methods of Wu and Proia (165) using 2 pairs of 
primers: 5’-ATGAAGGTCTCCACCACTGC-3’ (wild type, exon 1),  
5’-AGTCAACGATGAATTGGCG-3’ (wild type, exon 2), 5’-
TAAAGCATGCTCCAGACT-3’ (mutant, neo cassette), and 5’-
CAAAGGCTGCTGGTTTCAAA-3’ (mutant, exon 2).  Primers were synthesized 
by Invitrogen (Carlsbad, CA), and REDExtract-N-Amp Tissue PCR Kit (Sigma, 
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St. Louis, MO) was used to amplify the DNA fragments, which were run on a 
1.5% agarose gel. 
 
Plasma analyses 
 Following a 5 h fast, mice were anesthetized with isoflurane and bled 
retro-orbitally using heparinized glass capillary tubes.  Fasting glucose was 
measured on whole blood using a One-Touch glucometer (Lifescan, Inc., 
Milpitas, CA).  Plasma was separated by centrifugation (12,000 rpm at 4˚C), 
aliquotted, and frozen at -20˚C for short term storage or -70˚C for long term 
storage.  Plasma total cholesterol and triglycerides (TGs) were measured by 
enzymatic colorimetric assays according to manufacturers’ directions adapted to 
a microtiter plate (Raichem, San Diego, CA).  Fast performance liquid 
chromatography (FPLC) was performed as described (48).  Plasma non-
esterified fatty acids (NEFAs) were also measured by enzymatic colorimetric 
assays from Wako (NEFA-C kit for Chapter III, NEFA-HR (2) kit for Chapters IV-
V; Richmond, VA).  Plasma fasting insulin was measured by radioimmunoassay 
(Chapters III and V) in Vanderbilt University’s MMPC Hormone Assay Core or by 
ELISA (Rat/Mouse Insulin ELISA Kit; Linco Research, Inc.; St. Charles, MO; 
Chapter IV). 
 
Harvesting of tissues 
 At the conclusion of each study, mice were euthanized with isoflurane 
followed by cervical dislocation and were perfused with PBS.  Cervical 
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dislocation was not performed when aortas were being collected (Chapter III and 
V).  Tissues were then harvested, weighed, frozen immediately in liquid nitrogen, 
and stored at -70˚C, unless otherwise specified.   
 
Bone marrow transplantation (Chapter III) 
 Donor mice were killed by cervical dislocation under anesthesia, and bone 
marrow was collected from the femurs and tibias.  Approximately 2-5 x 106 bone 
marrow cells were injected into lethally irradiated recipient mice via the 
retroorbital venous plexus.  Recipient mice were given antibiotic water (5 mg 
neomycin and 25,000 units polymyxin B sulfate per liter) for 1 week prior to and 2 
weeks following BMT.  Three separate BMT experiments were conducted as 
described below and diagrammed in Figure 3.1. 
 
BMT #1 
 Male and female LepR+/+;LDLR-/- mice were lethally irradiated at 6-9 
weeks of age and transplanted with marrow from LepR+/+;LDLR-/- or 
LepRdb/db;LDLR-/- donors.  Eight weeks post-BMT, mice were fed WD.  Mice were 
killed 21 weeks post-BMT.   
 
BMT #2 
 Female LepR+/+;LDLR-/- mice were lethally irradiated at 9-16 weeks of age 
and transplanted with marrow from LepR+/+;LDLR-/- or LepRdb/db;LDLR-/- donors.  
Starting 4 weeks post-BMT, mice were fed WD through the end of the study (8 
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weeks total).  Mice were assessed for adipose and muscle mass by NMR as 
described above.  After 4 weeks of WD feeding, mice began to receive daily 
injections of leptin or PBS control (see below) for 4 weeks and were then killed.   
 
BMT #3 
 Male and female obese, hyperleptinemic LepRdb/db;LDLR-/- mice were 
lethally irradiated at 9-13 weeks of age and transplanted with marrow from 
LepRdb/db;LDLR-/- or LepR+/+;LDLR-/- donors.  Mice remained on chow diet 
throughout the study and were killed 16 weeks post-BMT. 
 
Leptin injections (Chapter III) 
 Mice in BMT protocol #2 received leptin or vehicle injections daily for 4 
weeks.  Murine recombinant leptin (National Hormone & Peptide Program, 
Torrance, CA) was dissolved in PBS, and 125 μg was injected intraperitoneally in 
a volume of 200 μl, as previously used by Bodary et al. (8).  Leptin solution was 
made fresh each week and frozen at -20○C until use. 
 For the leptin half-life study, 9-week-old LepR+/+;LDLR-/- female mice were 
injected with leptin (125 μg) one time.  Plasma samples were obtained at 
baseline (2 h before injection), 30 min, 1 h, 3 h, 12 h, and 22 h post-leptin 
injection. 
 
 
 
 36 
Atherosclerosis quantification (Chapters III and V) 
 Hearts were preserved in OCT and immediately frozen on dry ice.  Fifteen 
10 μm sections were collected over a 300 μm range beginning at the aortic root, 
according to the method of Paigen et al. (111).  Aortic root sections were then 
stained for neutral lipids with Oil Red O (ORO) and counterstained with 
hematoxylin according to standard protocol.  Lesions were captured with a Q-
Imaging Micropublisher camera and quantified using Kinetic Histometrix 6 
imaging and analysis software (Kinetic Imaging, Durham, NC). 
 
Energy expenditure (Chapter IV) 
 After 8 wks on WD, representative male MIP-1α-/-, MIP-1α+/-, and MIP-
1α+/+ mice were housed individually in OxyMax cages (in Vanderbilt’s MMPC) 
and kept on a light/dark cycle of 12 h light, 12 h dark.  After an acclimation period 
of approximately 15 h, oxygen consumption data was recorded for a 24 h period, 
and energy expenditure (kcal/h) was calculated based on the (Vo2 rate)/(Vco2 
rate) ratio using software provided by Columbia Instruments.  Mice were weighed 
before and after being housed individually, and the initial body mass was used 
for energy expenditure/body mass calculations.  The food in each cage was 
weighed at the beginning and end of the experiment to calculate food 
consumption per mouse. 
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Staining of WAT and liver sections 
 Perigonadal WAT was harvested from mice, weighed, and a portion was 
fixed overnight in 10% formalin, transferred to 70% ethanol, and paraffin 
embedded.  Tissue was cut into 7μm sections (HM325 microtome, Microm) and 
stained with 0.1% w/v toluidine blue solution (Newcomer Supply, Middleton, WI).  
Representative sections are shown.  Images were taken at 100x magnification.  
Liver sections were stained with oil red O and hematoxylin as previously 
described (23). 
 
Hepatic triglyceride content 
 After mice were killed, livers were weighed and frozen in liquid nitrogen.  
Measurement of TG content was conducted by the Lipid Core Lab of Vanderbilt’s 
MMPC as previously described (132).   
 
Real time polymerase chain reaction (PCR) 
 Tissues for RNA extraction were harvested and immediately frozen in 
liquid nitrogen before being stored at -70˚C.  RNA was isolated from tissues 
using the RNeasy Mini Kit (Qiagen) and RNA concentration was quantified by 
measuring optical density at 260 nm.  BioRad’s iScript cDNA Synthesis kit was 
used to synthesize cDNA.  An iQ5 thermal cycler (BioRad) was used in 
conjunction with iQ Supermix (BioRad) and individual Assay-on-Demand 
(Applied Biosystems) primer/probe sets for each gene.  The following genes 
were assessed: 18S (4352930E), Ccl2 (Mm00441242_m1),  
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Ccl3 (Mm00441258_m1), Ccl4 (Mm00443111_m1), Ccl5 (Mm01302428_m1), 
Emr1 (Mm00802530_m1), Cd68 (Mm00839636_g1), Cd3e (Mm00599683_m1), 
Saa1 (Mm00656927_g1), Tnfa (Mm00443258_m1), Il-10 (Mm99999062_m1), 
Arg1 (Mm01190441_g1), Adipoq (Mm00456425_m1),  
Foxp3 (Mm00475156_m1), Mgl1 (Mm00546124_m1), Mgl2 (Mm00460844_m1), 
Ccr1 (Mm00438260_s1), Ccr5 (Mm01216171_m1),  
Srebp-1c (Mm00550338_m1), and Scd-1 (Mm01197142_m1).  Relative 
expression was calculated by the ΔΔCt method using 18S expression to 
normalize the results. 
 
Migration assays 
 
Thioglycollate-elicited recruitment of immune cells to the peritoneal cavity 
Mice were injected intraperitoneally with 3 ml of 3% thioglycollate (Sigma) 
to induce sterile inflammation.  Three days later, peritoneal cells were harvested 
by lavage with 10 ml of serum-free DMEM, washed, and counted to determine 
the number of macrophages recruited to the peritoneal cavity.  Cells collected in 
this manner were used for the Boyden chamber assays. 
 
Boyden chamber migration assay 
The chemoattractants and vehicle control were loaded into the bottom 
wells of the Boyden chamber, covered by a cell-permeable membrane, and 
primary peritoneal macrophages from C57BL/6 (MIP-1α+/+) or MIP-1α-/- mice 
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were loaded on top of the membrane.  After a 2 h incubation at 37˚ with 5% CO2, 
cells that migrated to the bottom side of the membrane were fixed for 10 minutes 
in cold methanol, stained with crystal violet, and counted using a light 
microscope.  Five high powered fields were counted per well. 
 
Statistics 
 
Chapter III 
 The unpaired Student’s t-test was used to assess statistical significance.  
A p value of <0.05 was considered to be statistically significant.  Results are 
shown as mean ± standard error of mean (SEM). 
 
Chapters IV and V 
 GraphPad Prism software (version 4.01) was used for all statistical 
analyses.  Data was analyzed with 2-way ANOVA and Bonferroni’s post hoc test 
or by 1-way ANOVA followed by Tukey’s multiple comparison post hoc test, as 
indicated.  Two-way ANOVA was used to assess the relative contribution of 
multiple effects and to check for interactions between different conditions.  
Outliers were removed from the data if outside the range of the mean ± 2SD.      
p ≤0.05 was considered significant. 
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CHAPTER III 
 
 
THE ROLE OF MACROPHAGE LEPTIN RECEPTOR IN AORTIC ROOT 
LESION FORMATION 
 
 
Introduction 
 In the current worldwide obesity epidemic, over 1 billion adults are 
overweight, and at least 300 million of these individuals are obese.  In the United 
States, cardiovascular disease (CVD) is the number one cause of death, and 
over 80% of deaths from CVD are due to atherosclerosis-related diseases.  Due 
to the compounding effect of obesity on atherosclerosis (37, 97, 127, 151, 161), 
understanding mechanisms by which obesity increases risk of atherosclerosis is 
critical to providing knowledgeable treatment and prevention of this deadly 
disease.  
Leptin is a 16-kD protein secreted by adipocytes and represents one 
potential molecular link between obesity and atherosclerosis.  Circulating plasma 
leptin levels correlate with the percentage of body fat and/or body mass index in 
normal-weight and obese rodents and humans (28, 90).  Although leptin is a 
satiety factor that normally reduces appetite and promotes energy expenditure, 
many obese humans display hyperleptinemia and are considered leptin resistant 
(4).  Leptin has multiple biologic effects, both centrally and peripherally, and there 
is evidence that hyperleptinemia is an independent risk factor for myocardial 
infarction and atherosclerosis (139, 154).  
 There are six leptin receptor (LepR) isoforms.  Unlike the other isoforms, 
the long form of the receptor, isoform b, has a 302-amino acid cytoplasmic tail 
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and participates in intracellular signaling.  The long form of the LepR is primarily 
expressed on hypothalamic neurons, and LepR deficient (LepRdb/db) mice 
develop extreme obesity and hyperleptinemia.  Peripheral cells such as 
macrophages also express this isoform (95, 106).  Leptin has been shown to 
have several potentially atherogenic effects in macrophages.  Treatment of 
macrophages with recombinant leptin affects their cytokine production (88, 129, 
130), lipid metabolism (42, 106), phagocytic function (42, 88), proliferation (42, 
88, 129, 130), and oxidative stress (5, 83).  Because macrophages are key in the 
development and progression of atherosclerosis (85), it is possible that 
hyperleptinemia could promote atherogenesis via some of these macrophage-
specific effects. 
Recently, Bodary et al. (8) investigated the possible role of 
hyperleptinemia in atherosclerosis and thrombosis.  In their study, 
atherosusceptible apolipoprotein E deficient (apoE-/-) mice were injected daily 
with recombinant leptin for 4 weeks.  Mice receiving the leptin injections had a 
significant increase in lesion surface area in their brachiocephalic and carotid 
arteries as well as their thoracic aorta.  Although these experiments indicated 
that leptin may be a molecular link between obesity and CVD, the cell type 
mediating leptin’s effect was not identified.  In the experiments described in our 
current study, we have tested the hypothesis that hyperleptinemia promotes 
atherosclerosis at the aortic root via macrophage LepRs. 
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Results 
 To test our hypothesis that hyperleptinemia promotes atherosclerosis via 
macrophage LepR, three different BMT experiments were conducted (Figure 
3.1), and they will be discussed in detail below.  All donor and recipient mice 
were LDLR deficient, with or without LepR.  After transplantation, reconstitution 
with the correct donor marrow was confirmed by performing PCR for the LepR on 
DNA from whole blood or spleen tissue from recipient mice. As shown in 3.2, 
mice were completely reconstituted and expressed the LepR genotype of the 
donor marrow. 
BMT
0 8 21
0 4 8 12
0 16
WD Sacrifice
Sacrifice
SacrificeWD
BMT
BMT Leptin
BMT #1
LepR+/+;LDLR-/-
recipients
BMT #3
LepRdb/db;LDLR-/-
recipients
BMT #2
LepR+/+;LDLR-/-
recipients
 
 
Figure 3.1.  Time course diagrams for bone marrow transplantation 
experiments.  In each BMT, mice were lethally irradiated and transplanted 
with bone marrow from LepR+/+;LDLR-/- or LepRdb/db;LDLR-/- mice.  Numbers 
represent the weeks post-BMT.  “WD” represents the start of Western diet 
feeding.  In BMT #2, “Leptin” indicates the start of daily injections of 
recombinant leptin (125 μg) or vehicle control.  
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Bone Marrow Transplantation #1: Mice with an absence of macrophage LepR 
and mild hyperleptinemia 
 The first BMT was designed to test the hypothesis that the absence of 
macrophage LepRs would be atheroprotective in a setting of mild 
hyperleptinemia.  At 6-9 weeks of age, LepR+/+;LDLR-/- mice were lethally 
irradiated and transplanted with bone marrow from LepR+/+ or LepRdb/db donors.  
This BMT design resulted in mice with an absence of functional LepR in their 
hematopoietic cells, including macrophages.  Comparisons were made for male 
and female recipients separately (Table 3.1, which can be found at the end of the 
Results).  At sacrifice, body weight, glucose, NEFA, insulin and leptin levels were 
not different between the recipients of LepR+/+;LDLR-/- or LepRdb/db;LDLR-/- 
marrow.  TC and TG levels in male mice receiving LepRdb/db;LDLR-/- marrow were 
increased compared to controls (p<0.05); however, no differences in plasma 
lipids were noted in female mice.  Measurement of aortic root lesion area by 
Control LepRdb/db LepR+/+
LepRdb/db
LepR+/+
1 2 3 54 6 7 8 9 10 11
 
 
Figure 3.2.  PCR analysis of recipient blood DNA.  DNA was isolated from 
blood collected from transplanted mice. PCR analyses for the LepR were 
performed as described in Chapter II.  Lanes 1–3 are the PCR products of tail 
DNA from LepRdb/db, LepRdb/+, and LepR+/+ mice, respectively. Lanes 4–7 are 
PCR products from blood DNA of mice receiving LepRdb/db marrow, and 
lanes 8–11 are PCR products from blood DNA of mice receiving LepR+/+ 
marrow. 
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ORO staining revealed an increase in lesion area in female compared to male 
mice (Figure 3.3); however, within each gender the absence of LepR on 
hematopoietic cells did not affect lesion area.  
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Figure 3.3.  Aortic root lesion area in LepR+/+;LDLR-/- mice from BMT #1.  
Lethally irradiated LepR+/+;LDLR-/- recipients were reconstituted with 
LepR+/+;LDLR-/- or LepRdb/db;LDLR-/- bone marrow and placed on WD starting 
8 wks post-BMT and sacrificed 5 months post-BMT.  Aortic root lesions were 
stained with oil red O and quantified as described in the Methods section.  
Mouse gender and bone marrow genotype of the recipients are as follows: 
female LepR+/+;LDLR-/- (▲), female LepRdb/db;LDLR-/- (●), male LepR+/+;LDLR-
/- (▼), and male LepRdb/db;LDLR-/- (■).  n=6-8 mice per group.  
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Bone Marrow Transplantation #2: Mice with an absence of macrophage LepR 
and pharmacologically-induced extreme hyperleptinemia 
 As the presence or absence of LepR on hematopoietic cells did not impact 
atherosclerotic lesion area in LepR+/+;LDLR-/- recipient mice when they were 
exposed to only mild elevations in leptin, a similar experiment was conducted 
using daily injections of leptin to induce extreme hyperleptinemia.  At 9-16 weeks 
of age, female LepR+/+;LDLR-/- recipients were lethally irradiated and 
transplanted with bone marrow cells either with or without LepR expression.  
After 4 weeks on WD, mice began receiving leptin (125 μg) or vehicle (PBS) 
injections for an additional 4 weeks.  The resulting groups are labeled according 
to the genotype of their bone marrow and their injection treatment type: 1) 
LepR+/+;LDLR-/- Vehicle, 2) LepRdb/db;LDLR-/- Vehicle, 3) LepR+/+;LDLR-/- Leptin, 
and 4) LepRdb/db;LDLR-/- Leptin.   
 Body weight, abdominal adipose tissue and liver mass, as well as total 
body adipose tissue and muscle mass, were measured (Figure 3.4).  At baseline, 
no differences in body weight were observed among the four groups (Figure 
3.4A).  All groups had increased body weight after 4 weeks on WD.  After 
initiation of leptin injection, both groups receiving leptin had a significant 
decrease in body weight (p<0.05 at 2 and 4 weeks post-injection; Figure 3.4A 
and Table 3.2).  Both leptin-treated groups had significantly less abdominal 
adipose tissue compared to vehicle-treated groups at sacrifice (LepR+/+;LDLR-/- 
Leptin vs. LepR+/+;LDLR-/- Vehicle, p<0.005; LepRdb/db;LDLR-/- Leptin vs. 
LepRdb/db;LDLR-/- Vehicle, p=0.0001; Figure 3.4B).  Liver mass was also 
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decreased in both leptin-treated groups, although this reached significance only 
for the LepRdb/db;LDLR-/- Leptin group (p<0.005; Figure 3.4B).  Total body 
adipose tissue mass (as measured by NMR) was decreased by 45% in the 
LepR+/+;LDLR-/- Leptin group and by 49% in the LepRdb/db;LDLR-/- Leptin group 
compared to their respective controls (p<0.0001; Figure 3.4C).  Muscle mass 
decreased non-significantly by 3% in mice receiving leptin. 
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 The presence or absence of macrophage LepRs did not impact any 
plasma parameters when comparing mice within the vehicle- or leptin-treated 
groups (Table 3.2).  When comparing leptin- versus vehicle-treated recipients of 
the same marrow, some differences in plasma parameters were noted (Table 
3.2).  Leptin-treated LepRdb/db;LDLR-/- recipients demonstrated a reduction in TC 
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Figure 3.4.  Differences in body weight and tissue mass in 
LepR+/+;LDLR-/- mice during the BMT #2 experiment.  Lethally irradiated 
female LepR+/+;LDLR-/- recipients were reconstituted with LepR+/+;LDLR-/- 
or LepRdb/db;LDLR-/- bone marrow, fed WD for 8 weeks, followed by daily 
leptin injections for 4 of the 8 weeks.  Bone marrow genotype of the recipients 
and injection treatment are indicated as follows: LepR+/+;LDLR-/- Vehicle (▲), 
LepRdb/db;LDLR-/- Vehicle (●), LepR+/+;LDLR-/- Leptin (∆), and 
LepRdb/db;LDLR-/- Leptin(○).  n=7-10 mice per group.  (A) Body weight over 
the time course of the experiment.  *p<0.05 vs. respective leptin-treated 
groups.  (B) Tissue mass at sacrifice.  **p<0.005, ***p=0.0001, and ^p<0.005 
vs. respective vehicle-treated groups.  (C) Percent change in mass of adipose 
and muscle tissue over the 4 week injection period.  #p<0.0001 vs. respective 
vehicle-treated groups.  
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and TG levels compared to vehicle-treated controls (p<0.05).  Leptin-treated 
LepR+/+;LDLR-/- recipients displayed a reduction in TC and an increase in NEFA 
levels compared to vehicle-treated controls (p<0.01).  Plasma insulin levels were 
lower in the leptin-treated LepRdb/db;LDLR-/- and LepR+/+;LDLR-/- groups (p<0.05 
for LepR+/+;LDLR-/- group) compared to their respective vehicle controls.  
Surprisingly, a statistically significant decrease in plasma leptin levels was 
observed in both leptin-treated groups at sacrifice (p<0.05).  No differences in 
aortic root lesion area were detected among the groups (Figure 3.5). 
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Figure 3.5. Aortic root lesion area in female LepR+/+;LDLR-/- mice from 
BMT #2.  Lethally irradiated female LepR+/+;LDLR-/- recipients were 
reconstituted with LepR+/+;LDLR-/- or LepRdb/db;LDLR-/- bone marrow, fed WD 
for 8 weeks, followed by daily leptin injections for 4 of the 8 weeks.  Aortic 
root lesions were stained with ORO and quantified as described in the 
Methods section.  Bone marrow genotype of the recipients and injection 
treatment are indicated as follows: LepR+/+;LDLR-/- Vehicle (▲), 
LepRdb/db;LDLR-/- Vehicle (●), LepR+/+;LDLR-/- Leptin (∆), and 
LepRdb/db;LDLR-/- Leptin (○).  n=8-10 mice per group. 
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Half-life of Injected Leptin 
 Because endpoint circulating leptin levels were significantly lower in mice 
injected with leptin, we sought to investigate the half-life of injected recombinant 
leptin.  LepR+/+;LDLR-/- mice were injected with 125 μg of leptin and plasma leptin 
concentrations measured for up to 22 h post-injection (Figure 3.6).  Plasma leptin 
levels were dramatically elevated at 30, 60, and 180 minutes post-injection 
(p<0.0001).  By 12 h post-leptin injection, plasma leptin levels had returned to 
baseline in all of the mice. 
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Figure 3.6.  Measurement of plasma leptin following intraperitoneal leptin 
injection.  Lean female LepR+/+;LDLR-/-  mice were injected with 
recombinant leptin (125 μg).  Blood samples were collected at baseline (2 h 
before injection) and at 30 min, 1 h, 3 h, 12 h, and 22 h after injection, and 
plasma leptin values were quantified.  #p<0.0001 vs. baseline.  n=3-5 mice per 
time point. 
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Bone Marrow Transplantation #3: Mice with the presence of macrophage LepR 
and severe hyperleptinemia 
 As a third test of our hypothesis, obese hyperleptinemic LepRdb/db;LDLR-/- 
mice were transplanted with bone marrow from LepRdb/db or LepR+/+ donors.  The 
LepRdb/db; LDLR-/- recipients had naturally occurring hyperleptinemia (>100 
ng/ml) due to their deficiency of LepR and were also hyperlipidemic, similar to 
leptin deficient LDLR-/- mice (48, 51).  Thus they did not require the use of a high 
fat diet to induce atherosclerotic lesion formation.   This BMT was designed to 
test the atherogenicity of LepR when it is only expressed on macrophages and 
other hematopoietic cells in the presence of obesity accompanied by high serum 
leptin levels.  Mice were 9-13 weeks old at the time of transplantation, and were 
sacrificed 16 weeks post-BMT.   
 There were no differences in body weight, plasma lipids, or leptin levels 
between the two groups at sacrifice; however, plasma insulin levels were 
significantly lower in the LepR+/+;LDLR-/- recipients (p<0.05; Table 3.3). 
 No sexual dimorphism was detected among the groups when aortic root 
lesions were quantified by ORO staining, therefore data from male and female 
mice were combined.  Differences in lesion size were not observed between the 
mice with a global absence of LepR (LepRdb/db;LDLR-/- group) and those 
expressing LepR only on their hematopoietic cells (LepR+/+;LDLR-/- group), as 
shown in Figure 3.7. 
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Figure 3.7.  Aortic root lesion area in LepRdb/db;LDLR-/- mice from BMT 
#3.  Lethally irradiated LepRdb/db;LDLR-/- recipients were reconstituted with 
LepRdb/db;LDLR-/- or LepR+/+;LDLR-/- marrow by BMT.  Mice were kept on a 
standard chow diet for the duration of the study, and sacrificed 16 weeks post-
BMT. (A) Aortic root lesions were stained with ORO and quantified as 
described in the Methods.  Groups are labeled according to the bone marrow 
genotype of the recipients: LepRdb/db;LDLR-/- (●) and LepR+/+;LDLR-/- (▲).  
n=12-13 mice per group.  (B) Representative ORO stained sections. 
  
Table 3.1  Plasma parameters and body weight for LepR+/+;LDLR-/- recipients from BMT #1 at sacrifice 
 Females Males 
Donor Marrow LepR+/+;LDLR-/- LepRdb/db;LDLR-/- LepR+/+;LDLR-/- LepRdb/db;LDLR-/- 
n 6 6 7 8 
Body weight (g) 21.4 ± 1.1 20.8 ± 1.0 26.6 ± 1.3 25.0 ± 0.5 
Cholesterol (mg/dl) 873 ± 59 765 ± 44 904 ± 37 1093 ± 72* 
Triglycerides (mg/dl) 357 ± 38 276 ± 50 323 ± 65 568 ± 53* 
NEFAs (mEq/L) 0.71 ± 0.08 0.87 ± 0.07 0.88 ± 0.10 1.04 ± 0.12 
Glucose (mg/dl) 146 ± 11 147 ± 12 118 ± 5 130 ± 8 
Insulin (ng/ml) 3.43 ± 1.58 1.13 ± 0.20 3.40 ± 1.53 0.73 ± 0.11 
Leptin (ng/ml) 16.9 ± 2.9 12.8 ± 1.8 18.9 ± 3.9 12.4 ± 1.6 
 
LepR+/+;LDLR-/- recipients were transplanted with LepR+/+;LDLR-/- or LepRdb/db;LDLR-/- bone marrow.  Mice were placed on 
WD 8 weeks post-BMT and sacrificed 21 weeks post-BMT.    Plasma parameters were assayed as described in the 
Methods section.  Statistics were performed using a Student’s t-test to compare parameters of LepR+/+ and LepRdb/db 
recipients within each gender.   * p<0.05 vs. LepR+/+;LDLR-/- group.
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Table 3.2  Plasma parameters and body weight for LepR+/+;LDLR-/- recipients from BMT #2 
  Vehicle  Leptin 
Donor Marrow 
 
LepR+/+;LDLR-/- LepRdb/db;LDLR-/-  LepR+/+;LDLR-/- LepRdb/db;LDLR-/- 
n  8 10  9 9 
Body weight (g)  20.8 ± 0.9 21.0 ± 0.3  18.3 ± 0.4* 18.6 ± 0.7
§ 
Cholesterol (mg/dl)  820 ± 59 817 ± 46  691 ± 35 662 ± 34
† 
Triglycerides (mg/dl)  281 ± 14 287 ± 24  216 ± 8
‡ 226 ± 16† 
NEFAs (mEq/L)  0.96 ± 0.08 1.11 ± 0.19  1.36 ± 0.10
‡ 1.16 ± 0.11 
Glucose (mg/dl) 
 108 ± 10 127 ± 7  105 ± 6 107 ± 10 
Insulin (ng/ml)  1.15 ± 0.21 0.89 ± 0.13  0.67 ± 0.06* 0.63 ± 0.04 
Leptin (ng/ml)  10.6 ± 2.3 9.3 ± 1.4  4.8 ± 0.6* 4.7 ± 0.9
† 
Estimated average 
daily leptin (ng/ml)  10.6 ± 2.3 9.3 ± 1.4  348.6 348.5 
Female LepR+/+;LDLR-/- recipients were transplanted with LepR+/+;LDLR-/- or LepRdb/db;LDLR-/- bone marrow.  Mice were 
placed on WD 4 weeks post-BMT.  Eight weeks post-BMT, mice were injected daily with leptin (125 μg) or vehicle (PBS) 
for 4 weeks.  Mice were injected with leptin or vehicle 21-25 h before sacrifice.  Student’s t-tests were used to compare 
recipients of different bone marrow within treatment groups, and recipients of the same bone marrow in different treatment 
groups.  The average daily leptin levels were estimated using the area under the curve from Figure 3.6 to calculate the 
average elevation above basal leptin levels in leptin-injected mice.  * p<0.05 vs. LepR+/+;LDLR-/- Vehicle group;  † p<0.05 
vs. LepRdb/db;LDLR-/- Vehicle group;  ‡ p<0.01 vs. LepR+/+;LDLR-/- Vehicle group; § p<0.01 vs. LepRdb/db;LDLR-/- Vehicle 
group.
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Table 3.3  Plasma parameters and body weight for LepRdb/db;LDLR-/- 
recipients from BMT #3 
Donor Marrow LepRdb/db;LDLR-/- LepR+/+;LDLR-/- 
n 12 13 
Body weight (g) 48 ± 1 47 ± 1 
Cholesterol (mg/dl) 775 ± 29 723 ± 42 
Triglycerides (mg/dl) 430 ± 41 352 ± 30 
NEFAs (mEq/L) 0.86 ± 0.06 0.90 ± 0.08 
Glucose (mg/dl) 200 ± 28 234 ± 25 
Insulin (ng/ml) 17.8 ± 2.3 11.6 ± 1.5* 
Leptin (ng/ml) 153 ± 10 130 ± 13 
 
LepRdb/db;LDLR-/- recipients were transplanted with LepRdb/db;LDLR-/- or 
LepR+/+;LDLR-/- bone marrow and sacrificed 16 weeks post-BMT.  * p<0.05 vs. 
LepRdb/db;LDLR-/- group. 
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Discussion 
 We have addressed the role of macrophage LepR in aortic root 
atherosclerotic lesion formation through three distinct bone marrow 
transplantation studies.  First, we tested the hypothesis that an absence of LepR 
on macrophages would be atheroprotective in lean LDLR-/- mice (BMT #1).  
Second, we tested this same hypothesis under pharmacologically induced 
hyperleptinemia (BMT #2).  Finally, we tested the hypothesis that the presence of 
LepR only on hematopoietic cells such as macrophages would be pro-
atherogenic in obese hyperleptinemic mice (BMT #3).   Despite the use of these 
three approaches to test our overall hypothesis, analysis of aortic root cross 
sections did not reveal alterations in atherosclerotic lesion area due to the 
presence or absence of macrophage LepR.   
There is evidence that hyperleptinemia is associated with increased risk of 
cardiovascular disease in humans (139, 154).  Recent mechanistic studies 
related to the role of leptin in vascular health have focused on the four major cell 
types involved in atherogenesis: endothelial cells, smooth muscle cells, T 
lymphocytes, and macrophages.  Full-length LepR has been shown to be 
expressed on and capable of signal transduction in all four of these cell types 
(107, 114, 138).  Potential means by which leptin could cause macrophages to 
become pro-atherogenic include: increased inflammatory cytokine secretion (88, 
130), proliferation (42, 88, 129, 130), and oxidative stress (5, 83), as well as 
impaired lipid metabolism (15, 106).  Thus, we speculated that macrophages 
could be the cell type responsible for increased lesion formation in a setting of 
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hyperleptinemia.  However, our data, derived from three separate bone marrow 
protocols, do not support a role for macrophages in hyperleptinemia-associated 
aortic root lesion formation.   
Bodary et al. has shown significantly increased total lesion area in the 
thoracic aorta as well as the brachiocephalic and carotid arteries in apoE-/- mice 
receiving recombinant leptin (8).  One possible explanation for the differences 
between this and our current studies is that macrophages may not be the primary 
cell type responsible for hyperleptinemia-induced aortic root lesion formation.  In 
fact, recent studies by Bodary and colleagues have shown that leptin’s effects on 
neointimal formation after vascular injury are not attributable to bone marrow-
derived cells (9). However, other possibilities exist.  First, the animal model used 
was different.  We cannot rule out the possibility that leptin interacts with apoE, 
and that the combined deficiency of both is required to detect the atherogenic 
potential of leptin.  Second, it is possible that leptin has a greater effect in more 
advanced lesions.  The lesions in apoE-/- mice fed Western diet for 8 weeks are 
more advanced than those in LDLR-/- mice under the same conditions.  Third, the 
location of the lesions quantified was different between the two studies.  It is 
possible that leptin mediates more potent effects at sites other than the aortic 
root.   
In both the study by Bodary and colleagues (8), as well as a recent study 
by Chiba et al. (21) leptin was shown to mediate changes in the abdominal and 
thoracic aorta as well as smaller arteries such as the brachiocephalic.  This 
difference from our current finding in the aortic root is important to note because 
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these other vessels are encompassed by adipose tissue.  Leptin can be secreted 
from perivascular adipose tissue (52) and could modulate the activity of 
macrophages more directly in these vessels.  Our original hypothesis was that 
leptin would increase macrophage-driven atherogenesis by mediating 
inflammatory or lipid-related processes.  However, recent data from our lab has 
shown that leptin is a potent monocyte/macrophage chemoattractant (47).  Our 
current studies in the aortic root are unable to address the question of whether 
perivascular-derived leptin can influence macrophage recruitment to the artery 
wall.  
Our current data leave open the possibility that non-bone marrow-derived 
cells such as endothelial cells and smooth muscle cells mediate the pro-
atherogenic effects of leptin detected in other studies (4, 8).  LepRs are 
expressed on coronary endothelial cells, and hyperleptinemia has been shown to 
induce endothelial dysfunction (76) and nitric oxide production (152).  Other 
investigators have shown that leptin induces oxidant stress in endothelial cells as 
well as their proliferation and expression of matrix metalloproteinases, a process 
likely involved in plaque rupture (11).  Oda et al. have shown that leptin 
stimulates the proliferation and migration of rat aortic smooth muscle cells, a 
process that is involved in both intermediate atherosclerotic lesion formation and 
in restenosis after balloon injury (107).  Thus, it is possible that the atherogenic 
effects of leptin are via activation of these non-hematopoietic cells involved in 
lesion formation.  
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The leptin-treated mice in BMT #2 responded physiologically to the 
exogenously induced hyperleptinemia by losing weight, including a nearly 50% 
reduction in adipose tissue mass, which concurs with previous studies (8, 20).  At 
sacrifice, despite 4 weeks of daily leptin treatment, both leptin-treated groups had 
significantly lower plasma leptin levels than the vehicle-treated groups.  Thus, 
induction of hyperleptinemia via daily intraperitoneal injection resulted in reduced 
endpoint plasma leptin levels, probably due to the significant loss of adipose 
tissue, the main endogenous source of leptin.  To test the length of time that 
injected leptin stayed in the circulation plasma leptin levels were measured for up 
to 22 h post-injection.  Although this leptin half-life study did not indicate leptin’s 
chronic effects, it suggested that the leptin-treated mice in BMT #2 were exposed 
to hyperleptinemia for less than 12 h out of each day during the 4 week treatment 
period.  This short period of extreme hyperleptinemia was sufficient to induce 
loss of adipose tissue mass; however, the overall result was decreased plasma 
leptin levels at the end of the study.  Other methods of leptin treatment—such as 
twice daily injections, mini osmotic pumps, or adenovirus vectors—might induce 
hyperleptinemia more effectively in lean mice (9, 20) and therefore allow obesity 
and hyperleptinemia to be separately assessed.   
 In conclusion, although in vitro data (15, 42, 106, 130) have suggested a 
role for macrophages in the leptin mediated development of atherosclerotic 
lesions, our results, from three different in vivo BMT studies, do not support a 
role for hematopoietic cell derived LepRb in aortic root lesion formation. 
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CHAPTER IV 
 
IMPACT OF GLOBAL MACROPHAGE INFLAMMATORY PROTEIN-1α 
DEFICIENCY ON WHITE ADIPOSE TISSUE INFLAMMATION AND 
METABOLISM IN MICE 
 
Introduction 
 Pro-inflammatory macrophages and T-lymphocytes accumulate in the 
white adipose tissue (WAT) of obese mice and humans (124, 159, 164, 166).  
Research within this field has focused on multiple topics related to adipose tissue 
macrophages (ATMs) and T-lymphocytes, but many questions remain 
unanswered.  In particular, many of the factors that recruit immune cells to WAT 
during weight gain are still unknown.  
 One group of candidates for the recruitment of inflammatory cells into 
WAT is the family of “chemotactic cytokines”, referred to as chemokines, which 
induce chemotaxis of leukocytes.  According to their classic definition, 
chemokines are small, 8-10 kD proteins that share structural similarity.  
Chemokines have been implicated in chronic inflammatory diseases, such as 
atherosclerosis and rheumatoid arthritis, and, recently, obesity.  Many 
chemokines, including those mentioned here, are within the “CC” chemokine 
category in reference to a characteristic pair of cysteine residues.  
 Macrophage inflammatory protein-1α (MIP-1α), referred to in standard 
nomenclature as CCL3, is a CC chemokine with increased expression in obese 
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WAT humans and mice.  MIP-1α transcript and protein are significantly elevated 
in WAT of three different models of obese mice: Lepob/ob, LepRdb/db, and diet 
induced obese (63, 166).  Expression of MIP-1α and its receptors CCR1 and 
CCR5 is increased in omental and subcutaneous WAT from obese humans as 
compared with normal weight individuals (55).  Furthermore, expression of MIP-
1α and CCR1 in WAT is positively correlated with fasting plasma insulin 
concentrations in humans (55, 102, 160).  Therefore, as multiple reports have 
shown, WAT MIP-1α transcript and protein are elevated in obesity and correlated 
with fasting plasma insulin, but the consequences of this are unknown.   
 In order to determine the role of MIP-1α in the WAT of obese mice, we 
used a previously generated genetic model (29), MIP-1α deficient (MIP-1α-/-) 
mice.  Although these mice have been used for immunology studies, to our 
knowledge, no one has characterized their metabolic phenotype.  We 
hypothesized that secretion of MIP-1α from WAT increases recruitment of 
monocytes and T-lymphocytes during weight gain, and, therefore, that diet 
induced obese MIP-1α-/- mice would have fewer macrophages and T-
lymphocytes in their WAT as well as lower fasting plasma insulin when compared 
to MIP-1α+/+ mice.  By measuring WAT gene expression, body composition, 
energy expenditure, and hepatic inflammation and lipid accumulation, we were 
able to address the role of MIP-1α in metabolism and, specifically, in WAT 
inflammation. 
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Results 
 
Experimental design 
 Male and female MIP-1α-/-, MIP-1α+/-, and MIP-1α+/+ mice were started on 
WD at 8 wks of age (Figure 4.1).  Mice were weighed weekly and body 
composition was measured every 4 weeks.  Mice were bled at baseline and after 
16 wks on WD.  Mice were killed and their tissues harvested after 16 wks of WD 
feeding. 
 
Metabolic phenotype of diet induced obese mice 
 Total body mass, fat mass, and lean mass significantly increased during 
WD feeding (diet effect in males and females was p<0.0001 for each at 24 wks of 
age), but MIP-1α expression level did not affect these parameters in either 
gender (Figure 4.2).  Perigonadal and perirenal WAT, liver, kidneys, and spleen 
masses were unaffected by MIP-1α genotype in male and female mice on either 
diet (Tables 4.1 and 4.2).   
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Western diet
Male & female
MIP-1α+/+, MIP-1α+/-, & MIP-1α-/- littermate mice
Baseline 4 8 12 16
8 weeks of age
 
 
Figure 4.1.  Experimental design (Chapter IV). Numbers indicate wks on 
WD.  Body composition was measured at each week shown, and plasma 
parameters were determined at baseline and 16 wks post-WD.  Mice were 
weighed weekly. 
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 To compare the metabolic phenotype of MIP-1α-/- mice with MIP-1α+/+ and 
MIP-1α+/- mice more comprehensively, we measured energy expenditure of 
individually housed WD-fed male mice (n=7-9 mice per genotype) following 8 wks 
of WD feeding.  As expected, energy expenditure was elevated during the dark 
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Figure 4.2.  Body mass and total fat and lean mass in MIP-1α+/+, MIP-1α+/-, 
and MIP-1α-/- mice.  Mice were either started on WD (solid lines) at wk 8 or 
kept on CD (dashed lines).  Data shown is for the 16 wk study period: body 
mass for male (A) and female (B) mice, total fat mass measured by NMR for 
male (C) and female (D) mice, and total lean mass measured by NMR in male 
(E) and female (F) mice. □, MIP-1α+/+; , MIP-1α+/-; ▼, MIP-1α-/-.  
Abbreviations: CD, chow diet; WD, Western Diet. 
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hours relative to the light hours (p<0.0001, light effect).  Consistent with the 
absence of differences in body mass and fat mass, no significant differences in 
energy expenditure were detected among the mice with varying MIP-1α 
expression levels (Figure 4.3).  Likewise, daily food consumption was similar 
among MIP-1α-/-, MIP-1α+/-, and MIP-1α+/+ mice (Figure 4.4).   
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Figure 4.3.  Energy expenditure relative to body mass in male MIP-1α+/+, 
MIP-1α+/-, and MIP-1α-/- mice.  Energy expenditure is plotted to include all 
time points at which data was collected during a 24 h period (A).  Data is 
plotted as mean ± SEM for each group during the 12 h of light (left panel) or 
12 h of dark (right panel) of the 24 h light/dark cycle (B).  Mice were weighed 
at the start of the experiment, and their energy expenditure was analyzed 
relative to their body mass.  Abbreviations: EE, energy expenditure.  n=7-9 
mice/group. 
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Plasma parameters 
 Mean fasting blood glucose was significantly higher in MIP-1α-/- and MIP-
1α+/- male mice, relative to their MIP-1α+/+ littermates after 16 wks on WD 
(p<0.05), but among CD-fed mice, glucose concentrations did not differ (Table 
4.3).  Fasting plasma insulin concentrations for the WD-fed male and female 
mice were similar among all genotypes (Table 4.3).  Plasma NEFA 
concentrations in MIP-1α-/- and MIP-1α+/- male mice were significantly lower than 
plasma NEFAs of MIP-1α+/+ mice (p<0.05 relative to MIP-1α+/+ mice, Table 4.3).  
The absence of MIP-1α did not alter plasma cholesterol or TGs in males or 
females on either diet (Table 4.3). 
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Figure 4.4.  Daily food consumption of male mice after 8 wks on Western 
Diet.  Food consumption was measured while mice were individually housed 
during the energy expenditure experiment.  Change in food mass per hour 
was calculated and converted into grams per day.  n=7-9 male mice/group.  
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Gene expression in the WAT 
 Gene expression of macrophage markers F4/80 and CD68 were 
significantly elevated by WD feeding in both males and females (p≤0.05).  
However, gene expression of these macrophage markers was not influenced by 
MIP-1α genotype (Figure 4.5A-D).  Expression of CD3ε, a general T-lymphocyte 
marker, was significantly increased in WD-fed compared to CD-fed mice, but this 
was not altered by MIP-1α deficiency (Figure 4.5E-F; p<0.005, diet effect).  T-
regulatory lymphocyte infiltration of obese WAT, as measured by FoxP3 gene 
expression, was also not influenced by the absence of MIP-1α (Figure 4.5G-H).  
Regardless of diet, gene expression of MIP-1α was absent in MIP-1α-/- mice and 
highest in MIP-1α+/+ mice, and its expression was increased with WD feeding 
(Figure 4.5I-J; p<0.005 for genotype effect and diet effect, p<0.05 for diet x 
genotype interaction).   
 The expression pattern of MIP-1β was influenced by the expression level 
of MIP-1α such that male MIP-1α-/- mice had lower MIP-1β expression than MIP-
1α+/+ and MIP-1α+/- mice (Figure 4.5K).  In fact, both diet and genotype 
significantly affected MIP-1β expression in male mice (p<0.05 for diet effect, 
genotype effect, and diet x genotype interaction).  MIP-1β expression was 
increased by WD feeding in female mice (p<0.005), but the genotype effect was 
not significant (Figure 4.5L).  The CC chemokine RANTES was also elevated 
with obesity (Figure 4.5M-N; p<0.0005), and in male mice, its expression was 
significantly affected by MIP-1α expression level (p=0.05).  Gene expression of 
MCP-1, another CC chemokine, was elevated with obesity but unaffected by the 
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level of MIP-1α expression (Figure 4.5O-P; p<0.0005, diet effect).  The pro-
inflammatory cytokine TNFα and the insulin-sensitizing adipokine adiponectin as 
well as the anti-inflammatory markers arginase 1 and IL-10 (which is secreted by 
ATMs (170)) were expressed to a similar extent in MIP-1α-/-, MIP-1α+/-, and MIP-
1α+/+ WD-fed mice (Figure 4.6).   
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Figure 4.5.  WAT gene expression in 24 wk old CD- and WD-fed mice.  
Relative gene expression is shown for male (A, C, E, G, I, K, M, O) and 
female (B, D, F, H, J, L, N, P) MIP-1α+/+, MIP-1α+/-, and MIP-1α-/- mice.  
Mice were either fed CD for 24 wks or switched from CD to WD at 8 wks of 
age (for a total of 16 wks of WD feeding).  RNA was isolated from perigonadal 
WAT and used to synthesize cDNA, which was used for real time PCR.  Data 
was analyzed by 2-way ANOVA.  Abbreviations: CD, chow diet; DE, diet 
effect; GE, genotype effect; INT, diet x genotype interaction; WD, Western 
diet; WAT, white adipose tissue.
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 In males, after 16 wks on WD, gene expression of F4/80 and CD68 were 
on average at least 6-fold greater than they were in their lean counterparts.  In 
females, F4/80 and CD68 expression in WAT was significantly elevated relative 
to CD-fed females, but the differences were only about 2-fold or less.  To 
address the reason for these gender differences, we plotted linear regression 
curves of total fat mass versus macrophage marker gene expression for males 
and females (Figure 4.7).  The slopes were not statistically different for males as 
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Figure 4.6.  WAT gene expression in Western Diet-fed mice.  MIP-1α+/+, 
MIP-1α+/-, and MIP-1α-/- mice were fed Western Diet for 16 wks.  RNA was 
isolated from perigonadal WAT and used to synthesize cDNA, which was 
used for real time PCR.  Data shows the relative gene expression of 
adiponectin (A-B), TNFα (C-D), arginase-1 (E-F), and IL-10 (G-H). 
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compared with females for either F4/80 or CD68 expression, which implies that 
the males had a greater fold difference in ATM recruitment than the females due 
to their larger fat mass. 
 
 
 
Males
0.0 0.5 1.0 1.5 2.0 2.5
0
5
10
15
20
25
m=2.82  0.62
Relative F4/80 expresson
Fa
t m
as
s 
(g
)
Females
0.0 0.5 1.0 1.5 2.0 2.5
0
5
10
15
20
25
m=4.89  1.08
Relative F4/80 expresson
Fa
t m
as
s 
(g
)
Males
0.0 0.5 1.0 1.5 2.0 2.5
0
5
10
15
20
25
m=2.99  0.75
Relative CD68 expresson
Fa
t m
as
s 
(g
)
Females
0.0 0.5 1.0 1.5 2.0 2.5
0
5
10
15
20
25
m=4.15  1.01
Relative CD68 expresson
Fa
t m
as
s 
(g
)
A
D
B
C
Fa
t m
as
s 
(g
)
Fa
t m
as
s 
(g
)
Fa
t m
as
s 
(g
)
Fa
t m
as
s 
(g
)
 
 
Figure 4.7.  Correlation between total fat mass and macrophage markers.  
Relative gene expression of F4/80 (A-B) and CD68 (C-D) are plotted versus 
the total fat mass of individual mice after 16 wks on Western Diet.  Data from 
MIP-1α-/-, MIP-1α+/-, and MIP-1α+/+ mice have been analyzed together.  The 
slope (m) of each linear regression line is shown.  The slopes in A and B and 
in C and D do not differ significantly from each other. 
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WAT morphology 
 WAT tissue was sectioned and stained with toluidine blue O to compare 
the morphology of WAT from MIP-1α-/- mice with that of MIP-1α+/+ and MIP-1α+/- 
mice.  Adipocytes tended to be larger and crown-like structures were more 
frequently observed in male mice; however, the absence of MIP-1α did not 
appear to influence WAT morphology in either males or females, and crown-like 
structures were observed in all 6 groups of mice (Figure 4.8).   
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Leukocyte migration 
 Our main endpoint for this study was macrophage and T-lymphocyte 
migration to WAT in the WD-fed mice.  Because of this, we wanted to determine 
whether leukocytes from MIP-1α-/- mice are able to migrate similarly to leukocytes 
from MIP-1α+/+ mice.  To address this question we injected MIP-1α-/- and MIP-
MIP-1α+/-
MIP-1α+/+
MIP-1α-/-
Males Females
 
 
Figure 4.8.  Toluidine blue O stained WAT in mice after 16 wks of 
Western Diet feeding.  Perigonadal WAT was harvested from mice, 
weighed, and a portion was fixed overnight in 10% formalin, transferred to 
70% ethanol, and paraffin embedded.  Tissue was cut into 7μm sections and 
stained with toluidine blue O.  Representative sections are shown.  Images 
were taken at 100x magnification. 
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1α+/+ mice intraperitoneally with thioglycollate to induce sterile inflammation.  We 
then collected primary peritoneal cells (the majority of which are macrophages), 
counted the number of cells obtained per mouse and used these cells for 
migration experiments.  We used a Boyden chamber to measure the migration of 
cells to 4 different chemokines using the well-established chemoattractant C5a 
as a positive control.  MIP-1α deficiency did not interfere with the recruitment of 
immune cells to the peritoneal cavity (Figure 4.9).  In addition, peritoneal cells 
from both C57BL/6 (MIP-1α+/+) and MIP-1α-/- mice responded robustly to C5a 
(p<0.0001 vs. all other chemoattractants, Figure 4.10).  Cells from MIP-1α-/- mice 
migrated towards MIP-1α (p<0.0001 vs. all other chemoattractants), but for cells 
from MIP-1α+/+ mice response to MIP-1α was not significant.  With both 
genotypes, few cells migrated towards MCP-1, MCP-3, and MCP-5.  
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Figure 4.9.  Thioglycollate stimulated recruitment of cells to the peritoneal 
cavity.  C57BL/6 (MIP-1α+/+) and MIP-1α-/- mice were intraperitoneally injected 
with 3% thioglycollate to induce sterile inflammation.  After 3 days, immune 
cells that had been recruited to the peritoneal cavity were collected and 
counted with a hemacytometer.  n=5 mice/genotype. 
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Figure 4.10.  Migration of primary peritoneal cells towards 5 different 
chemoattractants.  Cells were harvested from the peritoneal cavity of 
thioglycollate-injected mice as described in the Methods.  Migratory ability of 
the cells was assessed using a Boyden chamber.  Chemoattractants were 
plated in duplicate or triplicate in the bottom wells of the Boyden chamber, 
cells from C57BL/6 (MIP-1α+/+) or MIP-1α-/- mice were placed in the upper 
wells, and a membrane was sandwiched between the cells and the 
chemoattractants.  Cells that migrated through the pores of the membrane 
during a 2 hour incubation period were fixed on the membrane, stained with 
Crystal Violet, and counted.  Graph shows the mean ± SE for 4 replicates, and 
cells were counted in 5 high powered fields (HPF) per well.  *p<0.0001 vs. all 
chemokines besides C5a, ^p<0.0001 vs. all chemokines other than MIP-1α. 
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Liver phenotype 
 Because the liver plays a critical role in lipid metabolism and hepatic 
steatosis is often present in obese mice, we measured hepatic TG 
concentrations and visualized hepatic neutral lipid accumulation with oil red O 
staining of liver sections.  MIP-1α deficiency did not influence the TG content of 
the liver, although males had significantly more hepatic TGs than females after 
16 wks on WD (Figure 4.11B; p<0.0001 for gender effect), which was also 
reflected by oil red O staining (Figure 4.11A).  As shown in Figure 4.12, absence 
of MIP-1α did not impact liver gene expression of F4/80, CD68, or pro-
inflammatory serum amyloid A1 (Saa1), TNFα, and MCP-1.  Expression of Saa1 
and MCP-1 were significantly lower in females than in males (p<0.0001).   
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Figure 4.11.  Hepatic triglyceride content in Western Diet-fed male and 
female MIP-1α+/+, MIP-1α+/-, and MIP-1α-/- mice.  Representative oil red O 
stained liver sections (A) and quantitative analysis of hepatic TGs in mice after 
16 wks of Western Diet feeding (B) are shown.  Hepatic TGs were measured 
as described in the Methods.  Abbreviations: TGs, triglycerides. 
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Figure 4.12.  Hepatic gene expression in male and female mice after 16 
wks on Western Diet.  RNA was isolated from liver and used to synthesize 
cDNA, which was used for real time PCR.  Data from males and females were 
analyzed by 2-way ANOVA using the same real time PCR threshold.  
Abbreviation: GND=gender effect. 
  
Table 4.1  Tissue masses in mice at 24 weeks of age 
 
Perigonadal WAT Mass (g) Liver Mass (g) Genotype 
CD WD CD WD 
Males     
MIP-1α+/+ 0.32 ± 0.02  2.18 ± 0.10 1.13 ± 0.09 2.83 ± 0.25 
MIP-1α+/- 0.34 ± 0.02  2.02 ± 0.06 1.12 ± 0.02 2.68 ± 0.14 
MIP-1α-/- 0.33 ± 0.02 1.98 ± 0.05 1.15 ± 0.03 3.07 ± 0.13 
Females     
MIP-1α+/+ 0.27 ± 0.05  1.17 ± 0.14 0.85 ± 0.03 1.46 ± 0.08 
MIP-1α+/- 0.26 ± 0.03  0.98 ± 0.12 0.93 ± 0.03 1.41 ± 0.08 
MIP-1α-/- 0.23 ± 0.02  0.98 ± 0.09 0.92 ± 0.05 1.45 ± 0.06 
Data shown is mean ± SEM.  Abbreviations: CD, chow diet; WD, Western Diet. 
 
Table 4.2  Tissue masses of 24 wk old mice   
 
Perirenal WAT (mg) Spleen (mg) Kidneys (mg) Genotype 
CD WD CD WD CD WD 
Males       
MIP-1α+/+ 68 ± 9 930 ± 76  72 ± 11 103 ± 6 341 ± 19 379 ± 13 
MIP-1α+/- 92 ± 12 866 ± 39  63 ± 20 103 ± 4 324 ± 12  376 ± 9 
MIP-1α-/- 72 ± 16 955 ± 41 71 ± 4 111 ± 6 339 ± 13 369 ± 9 
Females       
MIP-1α+/+ 99 ± 19  622 ± 74 63 ± 2  117 ± 7 247 ± 11 285 ± 8 
MIP-1α+/- 66 ± 5* 587 ± 80 73 ± 5  111 ± 5 260 ± 8 273 ± 7 
MIP-1α-/- 96 ± 13 566 ± 54 68 ± 5 118 ± 5  246 ± 9 262 ± 10 
Data shown is mean ± SEM.  *p<0.05 for one-way ANOVA, but Tukey’s Multiple Comparison Test revealed no significant 
differences between MIP-1α+/+, MIP-1α+/-, and MIP-1α-/- female mice.  Abbreviations: CD, chow diet; WD, Western Diet. 
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Table 4.3  Plasma parameters in mice at 24 weeks of age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mice were 8 wks old when started on WD.  Data shown is mean ± SEM and was analyzed using 1-way ANOVA with 
Tukey’s Multiple Comparison Test.  *p<0.05 and **p<0.001 vs. WD-fed MIP-1a+/+ males.  ^Blood glucose measurements 
were only obtained for 3 (male MIP-1α+/+) or 14 (female MIP-1α+/-) mice.  Variation in “n” is due to the removal of outliers 
(see Methods).  Abbreviations: TC, total cholesterol; TG, triglyceride; NEFA, non-esterified fatty acid; ND, not determined. 
 
Genotype n Glucose 
(mmol/l) 
Insulin 
(ng/ml) 
TC 
(mmol/l) 
TG 
(mmol/l) 
NEFA 
(mEq/l) 
Chow Diet 
Males       
MIP-1α+/+ 4^ 5.66 ± 0.44 ND 1.86 ± 0.18 0.55 ± 0.02 1.19 ± 0.19 
MIP-1α+/- 16 5.77 ± 0.22 ND 1.68 ± 0.05 0.54 ± 0.01 0.79 ± 0.10 
MIP-1α-/- 7 5.44 ± 0.33 ND 1.71 ± 0.05 0.57 ± 0.03 1.05 ± 0.11 
Females       
MIP-1α+/+ 6 5.22 ± 0.44 ND 1.24 ± 0.08 0.50 ± 0.02 0.74 ± 0.06 
MIP-1α+/- 15^ 5.05 ± 0.28 ND 1.30 ± 0.03 0.52 ± 0.01 0.77 ± 0.05 
MIP-1α-/- 6 5.05 ± 0.17 ND 1.30 ± 0.08 0.55 ± 0.02 0.80 ± 0.07 
Western Diet 
Males       
MIP-1α+/+ 14-15 6.83 ± 0.28 4.24 ± 0.82 4.82 ± 0.28 0.50 ± 0.02 0.73 ± 0.06 
MIP-1α+/- 29-32 7.70 ± 0.22* 3.29 ± 0.32 4.71 ± 0.13 0.54 ± 0.01 0.49 ± 0.03** 
MIP-1α-/- 22-24 7.66 ± 0.17* 3.42 ± 0.36 5.13 ± 0.16 0.53 ± 0.02 0.55 ± 0.04* 
Females       
MIP-1α+/+ 18-20 6.55 ± 0.22 1.06 ± 0.10 2.86 ± 0.13 0.44 ± 0.02 0.45 ± 0.04 
MIP-1α+/- 22-23 6.77 ± 0.22 0.81 ± 0.08 2.77 ± 0.10 0.41 ± 0.02 0.42 ± 0.02 
MIP-1α-/- 22-24 6.77 ± 0.22 0.91 ± 0.10 2.84 ± 0.10 0.43 ± 0.02 0.49 ± 0.03 
80
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Discussion 
 The elevation of MIP-1α in WAT of obese humans and mice is well-
established.  Based on its known ability to chemoattract monocytes, 
macrophages, and T-lymphocytes, we hypothesized that MIP-1α has an 
important role in the recruitment of these cells into WAT during diet induced 
weight gain.  Therefore, we predicted that MIP-1α-/- mice would have less 
accumulation of macrophages and T-lymphocytes in their WAT.  However, 
F4/80, CD68, and CD3ε were expressed to the same degree in diet induced 
obese MIP-1α-/- mice compared with obese MIP-1α+/+ mice.  Furthermore, in vitro 
migration experiments demonstrated that leukocytes from MIP-1α-/- mice retain 
their ability to migrate in response to inflammatory stimuli.  These data suggest 
that MIP-1α does not contribute to the recruitment of monocytes and T-
lymphocytes to WAT during DIO. 
 Gene expression of MIP-1β and RANTES in the perigonadal WAT was 
significantly affected by MIP-1α genotype.  It is possible that MIP-1α regulates 
the expression of MIP-1β as previous in vitro reports have established some 
precedence for one chemokine influencing the secretion of another chemokine in 
neutrophils (122, 123).  In particular, MIP-1α can induce secretion of TNFα (122), 
which can in turn stimulate chemokine secretion, and MIP-2/CXCL2 can induce 
MIP-1α secretion (123).  Due to the proximity of the MIP-1α gene to the MIP-1β 
and RANTES genes (0.01cM from MIP-1β gene and 0.2 cM from RANTES gene 
on chromosome 11), distal promoter or enhancer elements of the MIP-1β and 
RANTES genes might have been disrupted when a portion of the MIP-1α gene 
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was deleted to generate MIP-1α-/- mice (29).  An alternative explanation is that 
MIP-1β and RANTES might be expressed at lower levels in the original 129 
background strain and that, even after 10 backcrosses, the genomic sequences 
close to MIP-1α are still of the 129 origin. 
 Unlike MIP-1β and RANTES, expression of the chemokine MCP-1 was 
elevated in all WD-fed mice and unaffected by MIP-1α expression level.  The role 
of MCP-1 in recruitment of monocytes to WAT has been somewhat controversial 
(61, 65, 66, 74, 168), but there is evidence to demonstrate the likelihood that 
MCP-1 is involved in this process.  In our study, WAT relative gene expression of 
both F4/80 and CD68 significantly and positively correlated with MCP-1 
expression level in the WAT (Figure 4.13; r2=0.79 and r2=0.77, respectively; 
P<0.0001 for the slope’s deviation from zero).  Thus, our data support the idea 
the MCP-1 is distinct from other CC chemokines in its involvement in monocyte 
recruitment to WAT during obesity. 
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 We predicted that MIP-1α-/- mice would have lower fasting glucose and 
plasma insulin concentrations based on the improved insulin and glucose 
tolerance observed in other genetic models of chemokine deficiency, specifically 
in MCP-1-/-, CCR2-/-, and CXCL14-/- mice (66, 104, 158), and the fact that 
expression of MIP-1α in WAT is positively correlated with fasting plasma insulin 
concentrations in humans (55, 102, 160).  However, after 16 wks on WD, male 
MIP-1α-/- and MIP-1α+/- mice had higher fasting blood glucose levels than male 
MIP-1α+/+ mice, and blood glucose concentrations did not differ among female 
mice.  The cause of elevated blood glucose, but not plasma insulin, in male MIP-
1α-/- and MIP-1α+/- mice is not known.  It is possible that MIP-1α-/- and MIP-1α+/- 
mice have minor pancreatic dysfunction when challenged with WD.  In that case, 
elevated circulating glucose could subsequently increase the percentage of 
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Figure 4.13.  Correlation between MCP-1 expression and macrophage 
markers.  Relative gene expression of F4/80 and CD68 are plotted versus 
MCP-1 relative gene expression for individual mice after 16 wks on Western 
Diet.  Data from male MIP-1α-/-, MIP-1α+/-, and MIP-1α+/+ mice have been 
analyzed together.  Linear regression line is shown.  p values indicate the 
significance of each slope’s deviation from zero. 
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NEFAs that are re-esterified in the WAT, driving down the plasma NEFAs, as 
was observed in male MIP-1α-/- and MIP-1α+/- mice.  Since glucokinase and islet-
specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) regulate 
glucose-stimulated insulin secretion by the pancreas, expression of these genes 
may be affected by MIP-1α deficiency.  Alternatively, the lipolytic rate may be 
decreased in male MIP-1α-/- and MIP-1α+/- mice, in which case not only NEFAs 
but also plasma glycerol concentrations would be decreased.  Future 
experiments will be necessary to determine the source of these differences in 
plasma insulin and NEFAs. 
 We have recently used another model of MIP-1α deficiency to investigate 
its role in atherosclerosis.  In this model, we lethally irradiated low density 
lipoprotein receptor deficient (LDLR-/-) mice and then transplanted them with 
bone marrow from MIP-1α+/+ or MIP-1α-/- mice.  This yielded mice with MIP-1α 
deficiency only in their bone marrow derived cells (BMDCs, MIP-1α-/-→LDLR-/-) 
and mice with expression of MIP-1α in all of their cells (MIP-1α+/+→LDLR-/-).  
Similar to the WAT phenotype we observed in MIP-1α-/- mice, diet induced obese 
MIP-1α-/-→LDLR-/- mice did not differ from MIP-1α+/+→LDLR-/- mice in their 
expression of macrophage and T-lymphocyte markers (unpublished data).  Thus, 
two different models of MIP-1α deficiency in diet induced obese mice indicate 
that MIP-1α is not required for monocyte and T-lymphocyte accumulation in 
WAT. 
 Upregulation of MIP-1α is likely a consequence of the changes that occur 
in obese WAT such as excess exposure to lipids and inflammatory factors.  Both 
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murine and human macrophages express MIP-1α in vitro upon stimulation with 
very low density lipoprotein and pro-inflammatory stimuli (132, 170).  In addition, 
administration of free fatty acids upregulates MIP-1α release by 3T3-L1 
adipocytes via NFκB, a transcription factor which regulates inflammatory genes 
(63).  Therefore, we believe that initial changes in the WAT during the onset of 
obesity secondarily induce MIP-1α production by the adipocytes or immune cells.  
In agreement with this, MIP-1α protein is elevated in WAT of mice after 20 wks of 
high fat diet feeding, but not after 1 wk (63).  In contrast, other chemokines, 
including MCP-1, MCP-2, MCP-3, and MRP-2, are produced in WAT in response 
to 1 wk of high fat diet feeding (63).  In addition, high fat diet induces early 
infiltration of T-lymphocytes into WAT in mice (105).  Taken within the context of 
the literature, our data indicate that elevated MIP-1α in WAT is a consequence of 
obesity, but its contribution to inflammation within the WAT of obese mice 
remains undetermined.  
 In conclusion, our data demonstrate that simultaneously lowering the 
expression of 3 different CC chemokines—MIP-1α, MIP-1β, and RANTES—does 
not impact macrophage or T-lymphocyte accumulation in WAT of diet induced 
obese mice.  This indicates that although these pro-inflammatory chemokines are 
present in obese WAT, they do not contribute to macrophage recruitment to 
WAT, and their involvement in WAT inflammation is different than the role of 
MCP-1. 
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CHAPTER V 
 
METABOLIC PHENOTYPE OF HYPERLIPIDEMIC MACROPHAGE 
INFLAMMATORY PROTEIN-1α DEFICIENT MICE 
 
Introduction 
 Macrophage inflammatory protein-1α (MIP-1α), a member of the CC 
chemokine family, is elevated in the WAT of obese mice and humans.  Since 
MIP-1α is a chemoattractant of monocytes and T-lymphocytes, we previously 
hypothesized that it was important for the recruitment of leukocytes to WAT 
during obesity.  As demonstrated in Chapter IV, our data do not support this 
hypothesis.  Therefore, the consequence of the increased presence of MIP-1α in 
WAT of obese mice and humans remains unknown. 
 Hyperlipidemia previously has been associated with elevated leukocyte 
MIP-1α secretion in human and mouse studies.  Unstimulated human blood 
monocytes from hyperlipidemic patients secrete more MIP-1α than those of 
normolipidemic humans (53), and our laboratory has demonstrated that 
administration of VLDL increases MIP-1α gene expression by murine 
macrophages (132).  In addition, WD-fed LDLR-/- hyperlipidemic mice have a 
significant 11.4-fold increase in hepatic MIP-1α gene expression relative to 
LDLR-/- mice on a chow diet, but in WD-fed LDLR+/+ mice this effect is mild and 
non-significant (163).  These data suggest that monocytes and macrophages 
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secrete more MIP-1α under hyperlipidemic conditions in comparison to 
normolipidemic conditions. 
 Previous unpublished observations from our laboratory identified an 
unexpected phenotype in hyperlipidemic mice with bone marrow derived cell 
(BMDC) MIP-1α deficiency.  Briefly, LDLR-/- mice were lethally irradiated before 
being transplanted with bone marrow from MIP-1α+/+ or MIP-1α-/- mice (see 
Figure 5.1 for experimental design).  This resulted in mice with MIP-1α deficiency 
only in their BMDCs (MIP-1α-/-→LDLR-/-) and mice with expression of MIP-1α in 
all of their cells (MIP-1α+/+→LDLR-/-).  Surprisingly, we discovered that after 12 
wks of WD feeding the male MIP-1α-/-→LDLR-/- mice had 56% less total fat than 
the MIP-1α+/+→LDLR-/- mice with only slightly less lean mass, indicating that the 
lower fat mass accounted for most of the decrease in overall body mass (P<0.05, 
Figure 5.2).  MIP-1α-/-→LDLR-/- mice also had smaller atherosclerotic lesions 
(P<0.05 for females after 6 wks on WD and for males after 12 wks on WD, Figure 
5.3).   
 MIP-1α-/-;LDLR+/+ mice have a similar degree of adiposity as MIP-
1α+/+;LDLR+/+ mice (Chapter IV) and are not a suitable model for atherosclerosis 
studies, therefore we crossed MIP-1α-/- mice with LDLR-/- mice and bred their 
progeny to generate LDLR-/- mice that had produced no MIP-1α (MIP-1α-/-;LDLR-
/-), were heterozygous for MIP-1α (MIP-1α+/-;LDLR-/-), or had normal production of 
MIP-1α (MIP-1α+/+;LDLR-/-).  We used these mice to determine whether 
hyperlipidemia was responsible for the smaller WAT mass and lesions observed 
in the MIP-1α-/-→LDLR-/- mice.  We hypothesized that WD-fed MIP-1α-/-;LDLR-/- 
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mice would have less total fat mass and smaller atherosclerotic lesions than MIP-
1α+/+;LDLR-/- mice. 
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Figure 5.1.  Experimental design of bone marrow transplantation study.  
“BMT” indicates time of bone marrow transplantation.  “WD” indicates 
transition from chow diet to Western Diet, and mice were fed WD for either 12 
or 6 wks.  Mice were euthenized at the end of study, designated “Sac”. 
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Figure 5.2. Time course of body weight, lean, and fat mass in male mice.  
LDLR-/- mice were transplanted with MIP-1α+/+ or MIP-1α-/- bone marrow. At 4 
weeks post-BMT, mice were placed on WD for either 6 or 12 weeks.  Body 
weight as well as total body lean and fat mass were measured by NMR pre-BMT, 
4 weeks post-BMT and at 6 and 12 weeks post-WD.  There were no differences 
between the two transplantations groups at pre-BMT, 4 weeks post-BMT, and 6 
weeks post-WD, thus, these values are presented for both cohorts of mice 
together.  The 12 week post-WD data represent only the mice sacrificed at that 
time point.  *p<0.05, **p<0.01, ***p<0.0005, ^p<0.0001 
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Figure 5.3. Recipients of MIP-1α-/- bone marrow have reduced lesion 
area.  LDLR-/- mice were transplanted with MIP-1α+/+ or MIP-1α-/- bone 
marrow. At 4 weeks post-BMT, mice were placed on WD for 6 or 12 weeks. 
Aortic root lesion area was quantified according to the Methods section. 
Panels A and B show lesion area from female and male mice after 6 weeks of 
WD feeding, respectively. Data are presented as mean ± SEM from 7-14 mice 
per group. Panels C and D show the lesion area from female and male mice 
after 12 weeks of WD feeding, respectively. Data are mean ± SEM from 7-13 
mice per group.  
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Results 
 
Experimental design 
 Male and female MIP-1α+/+;LDLR-/-, MIP-1α+/-;LDLR-/-, and MIP-1α-/-; 
LDLR-/- mice were started on WD at 8 wks of age.  Mice were weighed weekly, 
body composition was measured every few weeks, and mice were bled at 
baseline and after 12 wks on WD (Figure 5.4). 
 
Plasma lipids, insulin, and glucose 
 FPLC was used to separate plasma cholesterol and TGs by density.  
Plasma TC was significantly increased in male and female mice after 12 wks of 
WD (P<0.01 AUC for baseline vs. AUC for 12 wks on WD, Figure 5.5), with a 
dramatic increase in the IDL/LDL fraction.  Plasma TC, TGs, and NEFAs were 
significantly higher in male than in female mice (p<0.0001 for TC and TGs and 
p<0.05 for NEFAs, gender effect).  After 12 weeks on WD, male MIP-1α-/-;LDLR-/- 
mice had significantly lower plasma NEFAs relative to MIP-1α+/+;LDLR-/- mice 
(p<0.05, Table 5.1).  Plasma TGs were lower in male MIP-1α-/-;LDLR-/- mice, as 
shown by plasma TG FPLC and enzymatic assay (Figure 5.6 and Table 5.1), but 
this difference was not significant.  No other differences among plasma lipids 
were observed in mice after 12 wks of WD feeding.  Plasma glucose, insulin, and 
leptin concentrations were significantly higher in male than in female mice 
(p<0.0001, gender effect; Table 5.1).  These parameters were unaffected by 
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MIP-1α expression, although plasma insulin concentrations in male MIP-1α+/- 
LDLR-/- mice were elevated non-significantly (p=0.076). 
 
 
 
Western diet
Male & female
MIP-1α+/+;LDLR-/-, MIP-1α +/-;LDLR-/-, and MIP-1α-/-;LDLR-/-
Baseline 4 8 12
8 weeks of age
6
 
 
Figure 5.4.  Experimental design (Chapter V).  Numbers indicate wks on 
WD.  Body composition was measured at each week shown, and plasma 
parameters were determined at baseline and 12 wks post-WD.  Mice were 
weighed weekly. 
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Figure 5.5.  FPLC analysis of lipoprotein profiles (cholesterol).  Plasma 
lipids were fractionated and cholesterol quantified as described in the 
Methods section. MIP-1α+/+;LDLR-/- mice are represented by squares, MIP-
1α+/-;LDLR-/- mice are represented by circles, and MIP-1α-/-;LDLR-/- mice are 
represented by triangles. A, males at baseline (just before start of WD 
feeding); B, females at baseline; C, males at 12 weeks post-WD; D, females 
at 12 weeks post-WD.  
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Body composition 
 When the mice were 8 wks old, we took baseline body composition 
measurements.  Among male mice, MIP-1α genotype did not influence baseline 
body mass or total lean and fat mass (Table 5.2 and Figure 5.7).  Female MIP-
1α-/-;LDLR-/- mice weighed significantly more (p<0.005 vs. MIP-1α+/-;LDLR-/- and 
MIP-1α+/+;LDLR-/- mice, 1-way ANOVA) and had significantly more lean mass 
(p<0.01 vs. MIP-1α+/+;LDLR-/- mice) at 8 wks of age, although their total fat 
masses were not different (Table 5.2 and Figure 5.7).  After 12 wks on WD, body 
weight, lean mass, and fat mass were not significantly different among the 
groups for either males or females (Table 5.3).  Similarly, the presence or 
absence of MIP-1α did not influence the mass of their various tissues, with the 
exception of female MIP-1α-/-;LDLR-/- mice, which had a significantly greater 
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Figure 5.6.  FPLC analysis of lipoprotein profiles (triglycerides).  Plasma 
lipids were fractionated and triglycerides quantified as described in the 
Methods section. MIP-1α+/+;LDLR-/- mice are represented by squares, MIP-
1α+/-;LDLR-/- mice are represented by circles, and MIP-1α-/-;LDLR-/- mice are 
represented by triangles. A, males at 12 weeks post-WD; B, females at 12 
weeks post-WD.  
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mean liver mass than MIP-1α+/+;LDLR-/- mice (p<0.05, Tukey’s Multiple 
Comparison post hoc test). 
 
Atherosclerosis 
 Atherosclerotic lesion area was quantified at the aortic root and no 
differences based on MIP-1α genotype were detected (Figure 5.8).  In addition, 
the male mice had similar lesion area to the female mice despite their nearly 2-
fold higher plasma TC concentrations. 
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Figure 5.7.  Body mass during WD feeding.  Mice were started on WD at 8 
wks of age.  Data shown is for the 12 wk study period: body mass for males 
(left) and females (right). 
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WAT gene expression and morphology 
 Expression of several genes involved in the immune response was 
quantified in perigonadal WAT (Figure 5.9).  Similar to what we previously 
observed in MIP-1α-/-;LDLR+/+ mice, expression of macrophage and T-
lymphocyte markers, F4/80 and CD3ε, were not significantly altered by MIP-1α 
deficiency (Figure 5.9A-B).  The inflammatory cytokine TNF-α as well as IL-10 
and Mgl2—markers of alternative activation—were expressed to a similar extent 
in all three genotypes (Figure 5.9C-D, F).  However, expression of macrophage 
galactose N-acetyl-galactosamine specific lectin 1 (Mgl1), another marker of 
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Figure 5.8: Aortic root lesion quantification. Aortic root lesions were 
stained with oil red O and quantified (A) as described in the Methods.  (B) 
Representative oil red O stained sections from MIP-1α+/+;LDLR-/- (C & F),  
MIP-1α+/-;LDLR-/- (D & G), and MIP-1α-/-;LDLR-/- (E & H) mice. 
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alternatively activated (M2) macrophages, was decreased in male and female 
MIP-1α+/-;LDLR-/- mice (p<0.001 genotype effect, Figure 5.9E).  MIP-1α was 
reduced in the MIP-1α+/-;LDLR-/- mice compared to the MIP-1α+/+;LDLR-/- mice 
and was not detected in MIP-1α-/-;LDLR-/- mice (p<0.0001 genotype effect, Figure 
5.9G).  MIP-1β was reduced in the male MIP-1α-/-;LDLR-/- and MIP-1α+/-;LDLR-/- 
mice compared to MIP-1α+/+;LDLR-/- mice (p<0.05 genotype effect, Figure 5.9H).  
MIP-1α deficiency did not significantly impact expression of the chemokines 
MCP-1 and RANTES (Figure 5.9I-J).  Compared with males, females had lower 
expression of several of the genes examined: F4/80 (p<0.0001) , TNFα 
(p<0.0001), IL-10 (p<0.01), Mgl1 (p<0.001), MIP-1α (p<0.0001 gender effect, 
p<0.0001 interaction between genotype and gender effects), MIP-1β (p<0.005 
gender effect, p<0.05 interaction between genotype and gender effects), 
RANTES (p<0.005), and MCP-1 (p<0.0001, Figure 5.9). 
 WAT was stained with toluidine blue O to visualize tissue morphology, but 
we did not observe any obvious differences among genotypes (Figure 5.10). 
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Figure 5.9. WAT gene expression after 12 wks on WD.  RNA was isolated 
from perigonadal WAT and used to synthesize cDNA, which was used for real 
time PCR.  Data were analyzed by 2-way ANOVA.  Abbreviations: 
GND=gender effect, GE=genotype effect, INT=interaction between gender 
and genotype effects 
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Liver lipids and gene expression 
 Hepatic TG accumulation was significantly greater in male than in female 
mice (p<0.05) but was not influenced by MIP-1α expression level (Figure 5.11).  
Quantification of hepatic gene expression for inflammatory markers, TNFα and 
MCP-1; two of MIP-1α’s receptors, CCR1 and CCR5; and factors involved in lipid 
metabolism, sterol regulatory element binding protein-1c and stearoyl-CoA 
desaturase-1; revealed no differences based on genotype, but expression of 
CCR5 was higher in females than in males (p<0.005, Figure 5.12). 
 
 
Figure 5.10.  Toluidine blue O stained WAT in mice after 12 wks on 
Western Diet.  Perigonadal WAT was harvested from mice, weighed, and a 
portion was fixed overnight in 10% formalin, transferred to 70% ethanol, and 
paraffin embedded.  Tissue was cut into 7μm sections and stained with 
toluidine blue O.  Representative sections are shown.  Images were taken at 
100x magnification. 
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Figure 5.11. Hepatic triglyceride content in Western Diet-fed mice.  
Representative oil red O stained liver sections (A) and quantitative analysis of 
hepatic TGs in mice after 16 wks of Western Diet feeding (B) are shown.  
Hepatic TGs were measured as described in the Methods.  Abbreviations: 
TGs, triglycerides. 
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Figure 5.12.  Hepatic gene expression in male and female mice after 12 
wks on Western Diet.  RNA was isolated from liver and used to synthesize 
cDNA, which was used for real time PCR.  Data from males and females were 
analyzed by 2-way ANOVA using the same real time PCR threshold.  
Abbreviation: GND=gender effect.   
  
Table 5.1  Plasma Parameters after 12 Weeks of Western Diet Feeding 
 
Genotype n TC 
(mg/dl) 
TG 
(mg/dl) 
NEFA 
(mEq/l) 
Glucose 
(mg/dl) 
Insulin 
(ng/ml) 
Leptin 
(ng/ml) 
 
Male 
       
MIP-1a+/+;LDLR-/- 5 1238 ± 62  375 ± 51 3.05 ± 0.17 123 ± 6  1.35 ± 0.18 50.3 ± 10.6 
MIP-1a+/-;LDLR-/- 7-17 1139 ± 52  332 ± 26 3.13 ± 0.12  115 ± 4  2.27 ± 0.37 45.6 ± 6.1 
MIP-1a-/-;LDLR-/- 7-8 1076 ± 94 280 ± 31 2.50 ± 0.19*  118 ± 5 1.29 ± 0.26 46.1 ± 9.4 
 
Female 
       
MIP-1a+/+;LDLR-/- 8 659 ± 34 146 ± 17 2.36 ± 0.16 94 ± 9 0.49 ± 0.06 6.8 ± 1.4 
MIP-1a+/-;LDLR-/- 8-10 741 ± 46 179 ± 18 2.79 ± 0.24 104 ± 3 0.60 ± 0.10 10.4 ± 1.9 
MIP-1a-/-;LDLR-/- 8-11 790 ± 39 199 ± 27 2.43 ± 0.24  97 ± 4 0.50 ± 0.05 14.5 ± 4.7 
*p<0.05 vs. MIP-1α+/-;LDLR-/- (1-way ANOVA), p<0.05 vs. MIP-1α+/-;LDLR-/- (Tukey’s Multiple Comparison post hoc test) 
 
Table 5.2  Body composition at 8 wks of age 
 
Genotype n Body Weight (g) Total WAT 
Mass (g) 
Lean Tissue 
Mass (g) 
 
Male 
    
MIP-1a+/+;LDLR-/- 5 20.1 ± 0.7 1.49 ± 0.06 15.6 ± 0.6 
MIP-1a+/-;LDLR-/- 17 20.8 ± 0.3 1.43 ± 0.05 15.9 ± 0.2 
MIP-1a-/-;LDLR-/- 7-8 19.9 ± 0.7 1.63 ± 0.13 15.2 ± 0.5  
 
Female 
    
MIP-1a+/+;LDLR-/- 7-8 16.2 ± 0.4 1.44 ± 0.06 12.3 ± 0.3 
MIP-1a+/-;LDLR-/- 10 16.7 ± 0.2 1.38 ± 0.08 12.9 ± 0.2 
MIP-1a-/-;LDLR-/- 11 17.7 ± 0.2*§ 1.39 ± 0.09 13.6 ± 0.2§ 
*p<0.05 vs. MIP-1a+/-;LDLR-/-, §p<0.01 vs. MIP-1a+/+;LDLR-/- 
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Table 5.3  Body and Tissue Masses after 12 Weeks of Western Diet Feeding 
 
Genotype n Body Weight (g) Total WAT 
Mass (g) 
Lean Tissue 
Mass (g) 
Perigonadal 
WAT Mass (g) 
Liver Mass (g)
 
Male 
      
MIP-1a+/+;LDLR-/- 5 35.8 ± 1.8 11.3 ± 1.4 21.3 ± 0.5 1.65 ± 0.23 1.86 ± 0.17 
MIP-1a+/-;LDLR-/- 17 35.6 ± 0.8 10.9 ± 0.5 21.6 ± 0.3 1.59 ± 0.08 1.88 ± 0.08 
MIP-1a-/-;LDLR-/- 7-8 33.3 ± 0.9 10.0 ± 0.7 20.4 ± 0.3  1.33 ± 0.09 1.80 ± 0.10 
 
Female 
      
MIP-1a+/+;LDLR-/- 7-8 22.2 ± 0.7  3.0 ± 0.5 16.4 ± 0.4  0.34 ± 0.12 1.11 ± 0.06 
MIP-1a+/-;LDLR-/- 10 23.8 ± 0.6 4.0 ± 0.4 17.1 ± 0.3  0.45 ± 0.06 1.26 ± 0.07 
MIP-1a-/-;LDLR-/- 11 24.3 ± 1.0 4.6 ± 0.7 17.1 ± 0.5  0.54 ± 0.10 1.43 ± 0.11* 
*p=0.05 vs. MIP-1α+/+;LDLR-/- (1-way ANOVA), p<0.05 vs. MIP-1α+/+;LDLR-/- (Tukey’s Multiple Comparison post hoc test) 103
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Discussion 
 Using WD feeding to induce hyperlipidemia in MIP-1α-/-;LDLR-/- mice, we 
addressed the potential interaction between hyperlipidemia and MIP-1α.  Based 
on the literature, we expected that monocytes/macrophages exposed to high 
plasma VLDL (as they are in WD-fed LDLR-/- mice) would produce greater 
amounts of MIP-1α than monocytes/macrophages from normolipidemic mice.  In 
addition, when compared with 17 other cytokines/chemokines, MIP-1α alone is 
significantly elevated in the plasma of hyperlipidemic LDLR-/- or apolipoprotein E 
deficient mice (173).  Thus, we expected MIP-1α deficiency to have a greater 
impact on metabolic parameters in hyperlipidemic mice than in normolipidemic 
mice. 
 As shown in the results, MIP-1α-/-;LDLR-/- and MIP-1α+/+;LDLR-/- mice had 
similar body compositions with no differences in total fat mass or atherosclerotic 
lesion area.  Plasma cholesterol strongly correlates with atherosclerotic lesion 
area in mice, but in a gender specific manner as demonstrated in our studies.  In 
comparison with the bone marrow transplanted mice discussed in this chapter’s 
introduction, plasma TC concentrations in non-irradiated male LDLR-/- mice were 
twice as high (587 ± 34 and 634 ± 34 mg/dl in MIP-1α-/-→LDLR-/- and MIP-
1α+/+→LDLR-/- males, respectively, vs. 1238 ± 62, 1139 ± 52, and 1076 ± 94 
mg/dl in MIP-1α+/+;LDLR-/-, MIP-1α+/-;LDLR-/-, and MIP-1α-/-;LDLR-/- mice, 
respectively), and their lesion area was likewise 2-fold higher.  Thus, male LDLR-
/- mice did not develop lesions matching the lesion size of the females unless 
their plasma cholesterol concentrations were much higher than those of the 
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females.  Furthermore, irradiation and bone marrow transplantation greatly 
attenuated the rise in plasma TC only in the male mice, but the reason for this is 
unknown.   
 The higher liver mass in MIP-1α-/-;LDLR-/- as compared to MIP-1α+/+; 
LDLR-/- female mice does not appear to indicate liver-specific differences.  The 
increased liver mass corresponded to a general increase in body and lean mass 
throughout the study among the female mice that was significant at baseline but 
not significant after 12 wks on WD.  The similarity in hepatic lipid content and 
expression level of inflammatory genes among all of the female mice 
demonstrates that the increased liver mass did not represent a change in hepatic 
steatosis or inflammation. 
 WAT expression of MIP-1α was reduced in a stepwise manner according 
to the mice’s genotypes, but the expression of other genes examined was not 
significantly influenced by MIP-1α expression level, with the exception of Mgl1 
and MIP-1β.  The reason for Mgl1 being decreased in the MIP-1α+/-;LDLR-/- mice 
is unknown, but the decreased expression of MIP-1β is consistent with what we 
observed in MIP-1α+/-;LDLR+/+ and MIP-1α-/-; LDLR+/+ mice (Figure 4.5K). 
 In conclusion, our data demonstrate that despite occurrence of 
hyperlipidemia in MIP-1α-/-;LDLR-/- mice after 12 wks on WD, they were similar to 
MIP-1α+/+;LDLR-/- in nearly all of the metabolic parameters tested.  The literature 
gives evidence of a correlation between MIP-1α and hyperlipidemia, but we have 
shown that hyperlipidemia alone did not potentiate the effect of MIP-1α deficiency 
on weight gain, atherosclerosis, or inflammation.  Both adipocytes and stromal 
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vascular cells in WAT are sensitive to total body irradiation, and irradiated mice 
have smaller adipocytes, reduced WAT mass, and lower adipogenic 
differentiation potential of their adipocyte precursors (118).  Therefore, since the 
combination of MIP-1α deficiency and hyperlipidemia was not sufficient to protect 
mice from diet induced weight gain, we propose two potential reasons for the 
dramatic decrease in WAT mass observed in the bone marrow transplanted 
mice.  First, either MIP-1α is involved in adipocyte maturation or another aspect 
of adipose tissue expansion and the sudden absence of MIP-1α—rather than its 
absence throughout development—prevents compensation for its role, or, 
second, that lethal irradiation and MIP-1α deficiency synergistically lower the 
capacity of adipocytes for TG storage in LDLR-/- mice.   
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CHAPTER VI 
 
DISCUSSION 
 
Summary 
 In Chapter III we demonstrated that removal of LepR from all BMDCs did 
not influence atherosclerotic lesion formation.  This suggested that non-
hematopoietic cells, rather than macrophages, are potential mediators of leptin’s 
effects on aortic root lesion formation.  In Chapter IV, we demonstrated that 
although expression of MIP-1α increases as a consequence of weight gain this 
chemokine is not critical for the recruitment of monocytes and T-lymphocytes to 
WAT in mice with DIO.  Furthermore, the presence of hyperlipidemia (Chapter V) 
was not sufficient to attenuate fat mass gain or atherosclerosis in MIP-1α-/- mice 
during WD feeding.  In the following paragraphs we will discuss how perivascular 
WAT could influence atherosclerotic lesion formation as a local source of leptin 
and chemokines.  We will also summarize what is currently known about the 
timeline of events occurring in WAT inflammation during obesity and demonstrate 
how we think MIP-1α is involved.  In chapter VII we will discuss our overall 
conclusions and potential future directions of this doctoral work. 
 
Role of perivascular WAT 
 As mentioned in the Discussion of Chapter III, our experiments to evaluate 
the role of leptin in atherosclerotic lesion formation focused on lesions at the 
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aortic root.  However, other regions of the aorta are encompassed by more 
perivascular WAT than the aortic root, and leptin coming directly from the 
perivascular WAT might affect the development of lesions in a way that a general 
elevation in plasma leptin does not.  Because perivascular WAT mass increases 
with high fat diet feeding (52), we proposed in our discussion at that time that 
secretion of leptin from the perivascular WAT has a local effect on the artery wall 
in the abdominal and thoracic regions of the aorta.  Since the publication of our 
research (142), perivascular WAT has been further characterized as described 
below. 
 In comparison to subcutaneous and perirenal adipocytes, perivascular 
adipocytes are smaller and more irregularly shaped (17).  In vitro differentiated 
perivascular adipocytes have lower expression of adipogenic regulatory genes, 
decreased secretion of leptin and adiponectin, and elevated secretion of MCP-1, 
IL-8, and IL-6 relative to adipocytes from other depots (17).  This indicates that 
they are not as mature/differentiated as other adipocytes and are likely more 
inflammatory.  In chow-fed mice, leptin gene expression was much lower in 
perivascular WAT than it was in subcutaneous, epididymal, or perirenal WAT, 
and MIP-1α expression was similar in all of the depots (17) (Figure 6.1A).  A 
striking change occurred when mice were fed a high fat diet for 2 wks.  In 
perivascular WAT, expression of leptin rose nearly to 1000-fold its expression in 
chow-fed mice, and MIP-1α expression increased to 600-fold its expression in 
chow-fed mice (Figure 6.1B) (17).  Thus, when mice ate a high fat diet, 
perivascular WAT quickly became the depot with the greatest expression of MIP-
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1α.  In addition, because expression of leptin in the perivascular WAT of chow 
diet-fed mice was much lower than it was in other fat depots, the dramatic 
increase in leptin expression induced by high fat diet feeding caused leptin 
expression in perivascular WAT to become comparable to that of the other 
depots in high fat diet-fed mice. 
 
 
 
 
 
Figure 6.1. Real-time PCR determination of adiponectin, PPAR, FABP4, 
leptin, and MIP1α mRNA expression in subcutaneous (SQ), epididymal 
(EPI), perirenal (PR), and perivascular (PV) adipose tissues of C57BL/6 
mice fed a chow (A) or a high fat diet (B) for 2 weeks.  mRNA levels in A 
are expressed relative to subcutaneous adipose tissue data, whereas in B, 
levels are expressed relative to the corresponding depot in chow-fed mice. 
Values represent the mean SEM of 3 to 5 mice per group. *p<0.05 vs SQ data 
(A) or vs corresponding chow-fed data (B).  Adapted from Chatterjee et al. 
Circ Res. 2009 Feb 27;104(4):541-9. Epub 2009 Jan 2.  
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 Expression of leptin and MIP-1α in perivascular WAT is more sensitive to 
high fat diet induced regulation than in subcutaneous, epididymal, and perirenal 
WAT—at least at the timepoint examined.  Based on this, we believe that 
perivascular WAT has emerged as an important contributor to local inflammation 
in the artery wall.  In fact, in addition to the pro-inflammatory roles of leptin 
described in Chapter III, we have demonstrated in vitro that leptin is a 
chemoattractant for THP-1 monocytes (47).  We expect future studies detailing 
how perivascular WAT-derived leptin and chemokines contribute to 
atherosclerotic lesion development to enhance our comprehension of the 
interaction between obesity and CVD (Figure 6.2). 
 Because MIP-1α expression is so highly upregulated in perivascular WAT, 
perhaps studying the effect of MIP-1α deficiency in this fat depot in high fat diet 
fed mice could serve as a helpful model system for uncovering the general role of 
MIP-1α in WAT.  Initially, perivascular WAT could be isolated from high fat diet 
fed mice and examined by flow cytometry or immunostaining to detect the 
presence of specific leukocyte populations.  Findings within the perivascular 
WAT would hopefully generate new hypotheses to test in regard to why MIP-1α 
is elevated in visceral and subcutaneous fat depots. 
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The role of chemokines during the progression of obesity 
 
The role of MIP-1α in human WAT 
 As described in the Introduction (Chapter I), expression of MIP-1α and its 
receptors is elevated in obese humans.  In addition, several studies have found 
an association between insulin resistance and increased MIP-1α expression in 
Endothelial cells
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Elevated 
plasma chemokines
& leptin
Elevated 
chemokines
& leptin
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Atherosclerotic 
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KEY:
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Chemokines
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Figure 6.2.  Contribution of perivascular and visceral WAT to the 
elevation in local and circulating concentrations of leptin and 
chemokines during obesity.  Chemokine and leptin receptors are present on 
many different cell types including monocytes, macrophages, endothelial cells, 
smooth muscle cells, and T-lymphocytes.  While visceral WAT can influence 
the artery wall in an endocrine manner by secreting leptin and chemokines 
into the circulation, perivascular WAT is adjacent to the arterial wall adventia 
and can have a local effect. 
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human WAT.  Even though we demonstrated that WD-fed MIP-1α-/- mice did not 
differ from MIP-1α+/+ mice in the degree of WAT inflammation or plasma insulin 
concentration (Chapter IV), it remains possible that MIP-1α is an important 
contributor to obesity and insulin resistance in humans.  In fact, although many 
studies have indicated that the chemokine MCP-1 is important in monocyte 
mobilization from the bone marrow and recruitment to WAT during obesity (43), 
the results from MCP-1 deficient (MCP-1-/-) mice have been inconsistent (as 
described below).  Continued research in humans as well as a thorough 
understanding of the timeline of events that occurs during obesity-related WAT 
inflammation will address the reason for elevation of MIP-1α and other 
chemokines in WAT of obese individuals. 
 
The role of an alternate chemokine, MCP-1, in leukocyte recruitment to WAT 
To date, MCP-1 and its receptor CCR2 are the best-studied of the 
chemokine ligands and receptors for their role in macrophage accumulation in 
WAT and obesity-induced insulin resistance.  MCP-1 is upregulated at the mRNA 
and protein levels in mesenteric, epididymal, subcutaneous, and perirenal WAT 
of diet induced obese mice (168).  F4/80 and CD68 expression is also increased 
in these WAT depots (168).  In addition, in vitro migration experiments show 
increased macrophage migration to mesenteric WAT-conditioned media, and an 
antibody for MCP-1 blocks this migration (168).  
 Two different groups have engineered transgenic mice using the human 
adipocyte fatty acid binding protein (aP2) gene promoter to overexpress MCP-1 
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in WAT (65, 66).  WAT of the MCP-1 overexpressing mice contains more 
macrophages than WAT from wild type mice, and MCP-1 transgenic mice are 
insulin resistant and glucose intolerant, suggesting that MCP-1 may promote 
macrophage infiltration and insulin resistance during obesity.  In addition, 
attenuation of MCP-1 activity with a dominant negative approach, improved 
insulin sensitivity and glucose tolerance in both LepRdb/db and diet induced obese 
mice (66).  On the other hand, experiments with MCP-1-/- mice have yielded 
inconsistent results.  Kanda et al. found that diet induced obese MCP-1-/- mice 
had fewer ATMs and were more insulin sensitive and glucose tolerant although 
they demonstrated no differences in body weight relative to wild type controls 
(66).  In contrast, Inouye et al. observed significantly increased body weight in 
diet induced obese MCP-1-/- mice and possibly a slight increase in macrophage 
accumulation in WAT combined with decreased insulin sensitivity (61).  Kirk et al. 
found similar results to Inouye et al. except that they observed no differences in 
insulin or glucose tolerance (73).  In regard to the receptor CCR2, Lumeng et al. 
have demonstrated that CCR2 deficiency partially attenuates the recruitment of 
inflammatory monocytes into WAT, suggesting that inflammatory monocytes are 
recruited in CCR2-dependent and -independent ways (89). 
 As the field of obesity-related WAT inflammation advances, it is becoming 
more apparent that the inflammatory process in WAT is highly dynamic.  
Numerous cell types are involved and different chemokines are elevated at 
distinct times and in particular fat depots.  Thus, we believe that some of the 
variability observed in the studies related to MCP-1 and unexpected results in our 
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MIP-1α studies are due to the timepoints chosen and the adaptability of the 
immune system.  In the following section we will assimilate what is already 
known about the cell types and chemokines that contribute to WAT inflammation 
in mice and indicate some future experiments that are needed. 
 
The progression of inflammation in WAT during weight gain 
 Many groups have contributed to our current understanding of the 
inflammatory process in WAT during high fat diet feeding and weight gain.  
Figure 6.3 illustrates how cell populations and chemokine expression and 
production shift during high fat diet feeding.  Following is a synopsis of the 
literature on this topic.   
 After only one day of high fat diet feeding WAT secretion of MCP-1 
immediately increases in mice (63).  By day three of the high fat diet, neutrophils 
have infiltrated the WAT, and secretion of MCP-1, -2, and -3 are all elevated (38, 
63).  Neutrophils are retained in the WAT through day 7, at which point secretion 
of MRP-2 is also elevated (38, 63).  Interestingly, MCP-1 and MIP-1α have been 
implicated in neutrophil recruitment (125).  The early upregulation by MCP-1 
immediately before infiltration of neutrophils suggests that it may be involved; 
however, it is not likely that MIP-1α is important for this initial recruitment of 
neutrophils since MIP-1α is not upregulated as early as MCP-1. 
 The next leukocytes on the scene are the CD3+CD8+CD4- T-lymphocytes, 
which are present by the second week of the diet (105).  CD8+ T-lymphocytes 
remain in the WAT throughout the development of obesity and peak by 11-16 
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wks of high fat diet feeding (105).  Not as much is known about the role of CD19+ 
B-lymphocytes in this process, but their presence in WAT nearly doubles after 3 
wks on diet, and they are also increased after 6 wks (36).  The earliest timepoint 
at which the number of F4/80+ macrophages increases above that of lean mice is 
after 6 wks of high fat diet feeding (105).  Macrophages continue to accumulate 
in the WAT and peak at 16-26 wks after the initiation of the high fat diet (105, 
140).  The number of CD3+CD8-CD4+ T-lymphocytes begins to decrease by 
week 6 and remains decreased (105).  By 11 wks on the diet, fewer Foxp3+ Treg 
lymphocytes remain in the WAT, and their presence continues to be low (105). 
 An elevation in chemokines is one of the first events observed in WAT of 
mice fed a high fat diet, and many chemokines are upregulated in the WAT 
during the progression of obesity, some of which are indicated in Figure 6.3.  
MIP-1α expression is elevated by week 12 and continues to be elevated through 
26 wks of high fat diet feeding (Figure 4.5 and (63, 105, 166)).  Activated CD8+ T-
lymphocytes are one of the main cellular sources of MIP-1α (27, 71).  Nishimura 
et al. has demonstrated that in mice with pre-established obesity, administration 
of CD8 blocking antibody partially attenuates MIP-1α expression in the WAT 
(105).  Based on this, CD8+ T-lymphocytes are probably one—but not the only—
cellular source of MIP-1α during WAT inflammation.   
 MIP-1α is also a chemoattract for CD8+ T-lymphocytes.  However, as 
Figure 6.3 demonstrates, MIP-1α upregulation occurs after CD8+ T-lymphocyte 
recruitment to WAT, and the complete absence of MIP-1α does not interfere with 
WAT inflammation (Chapter IV).  Therefore, although Nishimura et al. have 
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demonstrated that CD8+ T-lymphocytes have a critical role in WAT inflammation 
and the subsequent development of systemic insulin resistance (105), we have 
demonstrated that MIP-1α is not essential for this.  As indicated by the multitude 
of references used to build the timeline in Figure 6.3, many groups are interested 
in understanding the contribution of chemokines to WAT inflammation.  Several 
studies have suggested that MIP-1α is important for recruitment of leukocytes to 
the WAT, but our work is the first to actually test this hypothesis.  Now that we 
have demonstrated that MIP-1α is not necessary for monocyte or T-lymphocyte 
recruitment to WAT in obesity, future studies can focus on whether MIP-1α plays 
a role in human obesity. 
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Figure 6.3.  Up- or downregulation of specific chemokines and 
leukocytes in WAT of high fat diet fed mice. Diagram indicates only the 
initial upregulation of each chemokine during high fat diet feeding and is based 
on the following references: Jiao et al. Diabetes 2009, Nishimura et al. Nature 
Medicine 2009, and Chapter IV.  Numbers on blue arrows represent the 
number of wks on high fat diet.  The initial reported increase or decrease in 
each cell type is shown; the horizontal arrows indicate that high fat diet fed 
mice continue to have more macrophages and CD8+ T-lymphocytes and 
fewer CD4+ T-lymphocytes and Treg lymphocytes throughout high fat diet 
feeding.  Additional sources used: Duffaut et al. BBRC 2009, Feurer et al. 
Nature Medicine 2009, Winer et al. Nature Medicine 2009, Rausch et al. I J 
Obesity 2007, Weisberg et al. JCI 2003, Xu et al. JCI 2003, Strissel et al. 
Diabetes 2007, Coenen et al. Diabetes 2007, Caspar-Bauguil et al. FEBS 
Letters 2005. 
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CHAPTER VII 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
Contribution of our research to understanding the roles of chemokines in 
WAT inflammation 
 Leukocytes have an essential role in atherosclerosis and obesity, which 
are both chronic inflammatory diseases.  Macrophages and T-lymphocytes are 
recruited to the artery wall and to WAT in response to pathological changes 
which occur within each tissue.  Chemokines and chemokine receptors are 
known to be important for lesion formation in atherosclerosis, but their role as 
initiators and propagators of WAT inflammation is not as clear.  Prior to the 
studies presented in Chapters IV and V, many groups observed elevated 
expression and production of MIP-1α in atherosclerotic lesions and in WAT of 
obese mice and humans, and MIP-1α levels were known to be associated with 
insulin resistance and hyperlipidemia.  However, the particular role of MIP-1α in 
the metabolic phenotype of lean, obese, or hyperlipidemic mice had not been 
tested.  We have extensively investigated the role of MIP-1α in metabolism in 
lean and obese mice and have shown that even when mice are challenged with 
WD, MIP-1α deficiency does not protect mice from atherosclerotic lesion 
development, WAT inflammation, elevated fasting plasma insulin, and hepatic 
steatosis.  Our data demonstrate that MIP-1α is not necessary for leukocyte 
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recruitment to the artery wall or WAT, suggesting that its elevation in these 
tissues might serve a different purpose than what we originally expected. 
 Furthermore, we demonstrated in multiple mouse models that the WD-
induced elevation in WAT expression of MIP-1β is attenuated in MIP-1α+/- and 
MIP-1α-/- male mice.  Therefore, we have demonstrated that a simultaneous 
reduction in MIP-1α and MIP-1β does not influence accumulation of 
macrophages or CD3+ T-lymphocytes in the WAT of diet induced obese mice. 
 
Future Directions 
 
A role in WAT inflammation that goes beyond chemotaxis 
 It is important to note that the role of chemokines and their receptors in 
atherosclerosis is not limited to chemotaxis.  They are involved in mobilization of 
cells from the bone marrow, cell adhesion, cell survival during differentiation, cell 
retention within the lesion, and lipid scavenging.  Therefore, while pursuing a 
better understanding of how chemokines participate in WAT inflammation as fat 
mass is increasing, experiments that test for the influence of chemokines on 
WAT properties besides accumulation of immune cells will be helpful.  Bone 
marrow transplantation of MIP-1α-/- BMDCs into lethally irradiated LDLR-/- mice 
dramatically attenuated fat mass gain without having an obvious effect on 
adipocyte size (Figure 5.2C and unpublished data).  Moreover, hepatic TGs were 
not elevated in MIP-1α-/-→LDLR-/- mice (unpublished data), ruling out the 
possibility that decreased lipid storage in the WAT was increasing ectopic lipid 
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storage in the liver.  A Cre/lox model could be used to remove MIP-1α expression 
from adult mice just before they are started on WD.  By measuring body 
composition in these mice at various times before and during WD feeding, we 
could test whether the sudden removal of MIP-1α is able to recapitulate the 
phenotype observed in MIP-1α-/-→LDLR-/- mice.  If it is, this would validate the 
findings from the bone marrow transplantation experiment and demonstrate that 
MIP-1α has a role in WAT expansion even without the stress of lethal irradiation.  
If removal of MIP-1α from adult mice is not able to reduce their sensitivity to diet 
induced weight gain, then this would indicate that lethal irradiation and/or bone 
marrow reconstitution are critical factors in the results of our bone marrow 
transplantation experiments. 
 As mentioned above, chemokines help to mobilize hematopoietic cells 
from the bone marrow.  During inflammatory conditions, such as high fat diet 
feeding, CCR2 and its receptors MCP-1 and MCP-3 are known to be involved in 
this mobilization process (149).  To see if MIP-1α also regulates BMDC 
mobilization we could place MIP-1α-/- and MIP-1α+/+ mice on WD and quantify 
specific populations of hematopoietic cells (using flow cytometry) in the bone 
marrow and blood.  As an important control we could measure CCR2, MCP-1, 
and MCP-3 in BMDCs to see whether MIP-1α deficiency alters expression of 
these proteins.  In addition, we could lethally irradiate MIP-1α-/- and MIP-1α+/+ 
mice and reconstitute them with MIP-1α-/- or MIP-1α+/+ bone marrow.  Using flow 
cytometry we could then quantify the various populations of hematopoietic cells 
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in the bone marrow and blood to test whether MIP-1α deficiency impedes 
reconstitution after lethal irradiation. 
 
Inflammation in the artery wall versus WAT 
 Although chemokines are abundantly expressed in WAT of obese mice 
and humans, many questions regarding their roles remain unanswered.  As 
research in this field continues it will be important to distinguish between the 
contributions of specific chemokines to the inflammation in the artery wall versus 
in the WAT.  Leukocyte infiltration of the artery wall has frequently served as a 
model of what might occur in WAT during the onset of obesity.  However, 
important differences between these two tissues are apparent.  For example, 
within the WAT, leukocytes circulate through small blood vessels and capillaries 
before extravasating into the tissue.  In contrast, athersclerosis occurs in the 
aorta (in mice) and in coronary arteries (in humans) in which blood is circulating 
with more force and in greater volume.  In addition, during obesity, WAT is 
actively growing to accommodate more lipid storage whereas the increased lipid 
storage in atherosclerosis is ectopic and pathogenic.  Furthermore, the 
populations of adipocytes proximal to the artery wall versus adipocytes in 
omental or subcutaneous WAT, for example, have distinct inflammatory 
properties, as demonstrated by Chatterjee et al. (17).  All of these differences 
could account for distinct roles of chemokines in each disease.  For instance, 
perhaps hypoxia plays a bigger role in recruitment of leukocytes into growing 
WAT whereas chemokines may be especially important for their participation in 
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leukocyte activation and adhesion to the endothelium in the arteries that are 
vulnerable to atherosclerosis.  Designing experiments based on the particular 
context in which leukocyte infiltration is occurring should provide insight into the 
role of not only MIP-1α but also of other chemokines.  Determining how 
inflammation in obesity and atherosclerosis progresses and how it can be 
resolved will be helpful for treating people suffering from either of these highly 
prevalent conditions. 
 123 
REFERENCES 
 
1. A Report of the NIH Obesity Research Task Force Strategic Plan for NIH 
OBESITY RESEARCH: U.S. Department of Health and Human Services, 2004. 
2. Statistics Related to Overweight and Obesity: U.S. Department of Health 
and Human Services, 2007. 
3. Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, Hytopoulos E, 
Iribarren C, Tsao PS, Tabibiazar R, and Quertermous T. Circulating 
chemokines accurately identify individuals with clinically significant 
atherosclerotic heart disease. Physiol Genomics 31: 402-409, 2007. 
4. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189: 47-60, 
2006. 
5. Beltowski J, Wojcicka G, and Jamroz A. Leptin decreases plasma 
paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel 
mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 
170: 21-29, 2003. 
6. Bischoff SC, Krieger M, Brunner T, Rot A, von Tscharner V, 
Baggiolini M, and Dahinden CA. RANTES and related chemokines activate 
human basophil granulocytes through different G protein-coupled receptors. Eur 
J Immunol 23: 761-767, 1993. 
7. Bluher S, Shah S, and Mantzoros CS. Leptin Deficiency: Clinical 
Implications and Opportunities for Therapeutic Interventions. J Investig Med, 
2009. 
8. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, and Eitzman DT. 
Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein 
E-deficient mice. Arterioscler Thromb Vasc Biol 25: e119-122, 2005. 
9. Bodary PF, Shen Y, Ohman M, Bahrou KL, Vargas FB, Cudney SS, 
Wickenheiser KJ, Myers MG, Jr., and Eitzman DT. Leptin regulates neointima 
formation after arterial injury through mechanisms independent of blood pressure 
and the leptin receptor/STAT3 signaling pathways involved in energy balance. 
Arterioscler Thromb Vasc Biol 27: 70-76, 2007. 
10. Boden G and Shulman GI. Free fatty acids in obesity and type 2 
diabetes: defining their role in the development of insulin resistance and beta-cell 
dysfunction. Eur J Clin Invest 32 Suppl 3: 14-23, 2002. 
 124 
11. Bouloumie A, Marumo T, Lafontan M, and Busse R. Leptin induces 
oxidative stress in human endothelial cells. FASEB J 13: 1231-1238, 1999. 
12. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, 
Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, and 
Weber C. Ccr5 but not Ccr1 deficiency reduces development of diet-induced 
atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27: 373-379, 2007. 
13. Breland UM, Halvorsen B, Hol J, Oie E, Paulsson-Berne G, Yndestad 
A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg WJ, Froland SS, 
Haraldsen G, Gullestad L, Damas JK, Hansson GK, and Aukrust P. A 
potential role of the CXC chemokine GROalpha in atherosclerosis and plaque 
destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol 
28: 1005-1011, 2008. 
14. Bruun JM, Lihn AS, Pedersen SB, and Richelsen B. Monocyte 
chemoattractant protein-1 release is higher in visceral than subcutaneous human 
adipose tissue (AT): implication of macrophages resident in the AT. J Clin 
Endocrinol Metab 90: 2282-2289, 2005. 
15. Cabrero A, Cubero M, Llaverias G, Alegret M, Sanchez R, Laguna JC, 
and Vazquez-Carrera M. Leptin down-regulates peroxisome proliferator-
activated receptor gamma (PPAR-gamma) mRNA levels in primary human 
monocyte-derived macrophages. Mol Cell Biochem 275: 173-179, 2005. 
16. Campfield LA, Smith FJ, Guisez Y, Devos R, and Burn P. Recombinant 
mouse OB protein: evidence for a peripheral signal linking adiposity and central 
neural networks. Science 269: 546-549, 1995. 
17. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, 
Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, 
Rudich S, and Weintraub NL. Proinflammatory phenotype of perivascular 
adipocytes: influence of high-fat feeding. Circ Res 104: 541-549, 2009. 
18. Chehab FF. Obesity and lipodystrophy--where do the circles intersect? 
Endocrinology 149: 925-934, 2008. 
19. Chen A, Mumick S, Zhang C, Lamb J, Dai H, Weingarth D, Mudgett J, 
Chen H, Macneil DJ, Reitman ML, and Qian S. Diet induction of monocyte 
chemoattractant protein-1 and its impact on obesity. Obes Res 13: 1311-1320, 
2005. 
20. Chen Y and Heiman ML. Chronic leptin administration promotes lipid 
utilization until fat mass is greatly reduced and preserves lean mass of normal 
female rats. Regul Pept 92: 113-119, 2000. 
 125 
21. Chiba T, Shinozaki S, Nakazawa T, Kawakami A, Ai M, Kaneko E, 
Kitagawa M, Kondo K, Chait A, and Shimokado K. Leptin deficiency 
suppresses progression of atherosclerosis in apoE-deficient mice. 
Atherosclerosis, 2007. 
22. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, 
Fortier M, Greenberg AS, and Obin MS. Adipocyte death defines macrophage 
localization and function in adipose tissue of obese mice and humans. J Lipid 
Res 46: 2347-2355, 2005. 
23. Coenen KR and Hasty AH. Obesity potentiates development of fatty liver 
and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-
deficient mice. Am J Physiol Endocrinol Metab 293: E492-499, 2007. 
24. Coleman DL. Effects of parabiosis of obese with diabetes and normal 
mice. Diabetologia 9: 294-298, 1973. 
25. Coleman DL and Hummel KP. Effects of parabiosis of normal with 
genetically diabetic mice. flc386 217: 1298-1304, 1969. 
26. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito 
B, Merval R, Proudfoot A, Tedgui A, and Mallat Z. Combined inhibition of 
CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and 
almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117: 
1649-1657, 2008. 
27. Conlon K, Lloyd A, Chattopadhyay U, Lukacs N, Kunkel S, Schall T, 
Taub D, Morimoto C, Osborne J, Oppenheim J, and et al. CD8+ and 
CD45RA+ human peripheral blood lymphocytes are potent sources of 
macrophage inflammatory protein 1 alpha, interleukin-8 and RANTES. Eur J 
Immunol 25: 751-756, 1995. 
28. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, 
Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, and et al. Serum 
immunoreactive-leptin concentrations in normal-weight and obese humans. N 
Engl J Med 334: 292-295, 1996. 
29. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, 
and Smithies O. Requirement of MIP-1 alpha for an inflammatory response to 
viral infection. Science 269: 1583-1585, 1995. 
30. Cross AK, Richardson V, Ali SA, Palmer I, Taub DD, and Rees RC. 
Migration responses of human monocytic cell lines to alpha- and beta-
chemokines. Cytokine 9: 521-528, 1997. 
 126 
31. Dahlman I, Kaaman M, Olsson T, Tan GD, Bickerton AS, Wahlen K, 
Andersson J, Nordstrom EA, Blomqvist L, Sjogren A, Forsgren M, 
Attersand A, and Arner P. A unique role of monocyte chemoattractant protein 1 
among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab 
90: 5834-5840, 2005. 
32. de Jager SC, Kraaijeveld AO, Grauss RW, de Jager W, Liem SS, van 
der Hoeven BL, Prakken BJ, Putter H, van Berkel TJ, Atsma DE, Schalij MJ, 
Jukema JW, and Biessen EA. CCL3 (MIP-1 alpha) levels are elevated during 
acute coronary syndromes and show strong prognostic power for future ischemic 
events. J Mol Cell Cardiol 45: 446-452, 2008. 
33. de Oliveira RT, Mamoni RL, Souza JR, Fernandes JL, Rios FJ, 
Gidlund M, Coelho OR, and Blotta MH. Differential expression of cytokines, 
chemokines and chemokine receptors in patients with coronary artery disease. 
Int J Cardiol 136: 17-26, 2009. 
34. De Rosa V, Procaccini C, Cali G, Pirozzi G, Fontana S, Zappacosta S, 
La Cava A, and Matarese G. A key role of leptin in the control of regulatory T 
cell proliferation. Immunity 26: 241-255, 2007. 
35. De Taeye BM, Novitskaya T, McGuinness OP, Gleaves L, Medda M, 
Covington JW, and Vaughan DE. Macrophage TNF-alpha contributes to insulin 
resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol 
Metab 293: E713-725, 2007. 
36. Duffaut C, Galitzky J, Lafontan M, and Bouloumie A. Unexpected 
trafficking of immune cells within the adipose tissue during the onset of obesity. 
Biochem Biophys Res Commun 384: 482-485, 2009. 
37. Eckel RH. Obesity and heart disease: a statement for healthcare 
professionals from the Nutrition Committee, American Heart Association. 
Circulation 96: 3248-3250, 1997. 
38. Elgazar-Carmon V, Rudich A, Hadad N, and Levy R. Neutrophils 
transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J 
Lipid Res 49: 1894-1903, 2008. 
39. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, 
Goldfine AB, Benoist C, Shoelson S, and Mathis D. Lean, but not obese, fat is 
enriched for a unique population of regulatory T cells that affect metabolic 
parameters. Nat Med 15: 930-939, 2009. 
40. Fonseca V. Effect of thiazolidinediones on body weight in patients with 
diabetes mellitus. Am J Med 115 Suppl 8A: 42S-48S, 2003. 
 127 
41. Fujioka Y and Ishikawa Y. Remnant lipoproteins as strong key particles 
to atherogenesis. J Atheroscler Thromb 16: 145-154, 2009. 
42. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, 
Nicola NA, Alexander WS, and Hilton DJ. Leptin can induce proliferation, 
differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci 
U S A 93: 14564-14568, 1996. 
43. Gautier EL, Jakubzick C, and Randolph GJ. Regulation of the migration 
and survival of monocyte subsets by chemokine receptors and its relevance to 
atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1412-1418, 2009. 
44. Gerhardt CC, Romero IA, Cancello R, Camoin L, and Strosberg AD. 
Chemokines control fat accumulation and leptin secretion by cultured human 
adipocytes. Mol Cell Endocrinol 175: 81-92, 2001. 
45. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis 
of obesity-related insulin resistance. Physiol Behav 94: 206-218, 2008. 
46. Gordon S and Taylor PR. Monocyte and macrophage heterogeneity. Nat 
Rev Immunol 5: 953-964, 2005. 
47. Gruen ML, Hao M, Piston D, and Hasty AH. Leptin requires canonical 
migratory signaling pathways for induction of monocyte and macrophage 
chemotaxis. Am J Physiol Cell Physiol, 2007. 
48. Gruen ML, Saraswathi V, Nuotio-Antar AM, Plummer MR, Coenen KR, 
and Hasty AH. Plasma insulin levels predict atherosclerotic lesion burden in 
obese hyperlipidemic mice. Atherosclerosis 186: 54-64, 2006. 
49. Guri AJ, Hontecillas R, Ferrer G, Casagran O, Wankhade U, Noble 
AM, Eizirik DL, Ortis F, Cnop M, Liu D, Si H, and Bassaganya-Riera J. Loss 
of PPARgamma in immune cells impairs the ability of abscisic acid to improve 
insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression 
and macrophage infiltration into white adipose tissue. J Nutr Biochem, 2007. 
50. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, 
Lallone RL, Burley SK, and Friedman JM. Weight-reducing effects of the 
plasma protein encoded by the obese gene. Science 269: 543-546, 1995. 
51. Hasty AH, Gruen ML, Terry ES, Surmi BK, Atkinson RD, Gao L, and 
Morrow JD. Effects of vitamin E on oxidative stress and atherosclerosis in an 
obese hyperlipidemic mouse model. J Nutr Biochem 18: 127-133, 2007. 
52. Henrichot E, Juge-Aubry CE, Pernin A, Pache JC, Velebit V, Dayer 
JM, Meda P, Chizzolini C, and Meier CA. Production of chemokines by 
 128 
perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? 
Arterioscler Thromb Vasc Biol 25: 2594-2599, 2005. 
53. Holven KB, Myhre AM, Aukrust P, Hagve TA, Ose L, and Nenseter 
MS. Patients with familial hypercholesterolaemia show enhanced spontaneous 
chemokine release from peripheral blood mononuclear cells ex vivo. 
Dependency of xanthomas/xanthelasms, smoking and gender. Eur Heart J 24: 
1756-1762, 2003. 
54. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, 
Furukawa S, Tochino Y, Komuro R, Matsuda M, and Shimomura I. Adipose 
tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 
56: 901-911, 2007. 
55. Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, 
Zlabinger GJ, and Stulnig TM. CC chemokine and CC chemokine receptor 
profiles in visceral and subcutaneous adipose tissue are altered in human 
obesity. J Clin Endocrinol Metab 93: 3215-3221, 2008. 
56. Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, 
Zlabinger GJ, and Stulnig TM. CC chemokine and CC chemokine receptor 
profiles in visceral and subcutaneous adipose tissue are altered in human 
obesity. J Clin Endocrinol Metab, 2008. 
57. Huber J. KF, Zeyda M., Prager G., Stulnig T. M. American Diabetes 
Association Conference, Chicago, IL, 2007. 
58. Hubert HB, Feinleib M, McNamara PM, and Castelli WP. Obesity as an 
independent risk factor for cardiovascular disease: a 26-year follow-up of 
participants in the Framingham Heart Study. Circulation 67: 968-977, 1983. 
59. Hummel KP, Dickie MM, and Coleman DL. Diabetes, a new mutation in 
the mouse. Science 153: 1127-1128, 1966. 
60. Ingalls AM, Dickie MM, and Snell GD. Obese, a new mutation in the 
house mouse. J Hered 41: 317-318, 1950. 
61. Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, Rollins BJ, and 
Flier JS. Absence of CC chemokine ligand 2 does not limit obesity-associated 
infiltration of macrophages into adipose tissue. Diabetes 56: 2242-2250, 2007. 
62. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, and 
Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice 
and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893, 
1993. 
 129 
63. Jiao P, Chen Q, Shah S, Du J, Tao B, Tzameli I, Yan W, and Xu H. 
Obesity-related upregulation of monocyte chemotactic factors in adipocytes: 
involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. 
Diabetes 58: 104-115, 2009. 
64. Kalra SP. Central leptin gene therapy ameliorates diabetes type 1 and 2 
through two independent hypothalamic relays; a benefit beyond weight and 
appetite regulation. Peptides 30: 1957-1963, 2009. 
65. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, 
Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, 
Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, 
Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, and Kadowaki T. 
Overexpression of monocyte chemoattractant protein-1 in adipose tissues 
causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602-
26614, 2006. 
66. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, 
Kitazawa S, Miyachi H, Maeda S, Egashira K, and Kasuga M. MCP-1 
contributes to macrophage infiltration into adipose tissue, insulin resistance, and 
hepatic steatosis in obesity. J Clin Invest 116: 1494-1505, 2006. 
67. Kang L, Sebastian BM, Pritchard MT, Pratt BT, Previs SF, and Nagy 
LE. Chronic ethanol-induced insulin resistance is associated with macrophage 
infiltration into adipose tissue and altered expression of adipocytokines. Alcohol 
Clin Exp Res 31: 1581-1588, 2007. 
68. Kannel WB, Wilson PW, Nam BH, and D'Agostino RB. Risk 
stratification of obesity as a coronary risk factor. Am J Cardiol 90: 697-701, 2002. 
69. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang 
BB, Bonaldo P, Chua S, and Scherer PE. Metabolic dysregulation and adipose 
tissue fibrosis: role of collagen VI. Mol Cell Biol 29: 1575-1591, 2009. 
70. Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, 
Aszmann O, Ludvik B, Silberhumer GR, Prager G, and Stulnig TM. 
Osteopontin expression in human and murine obesity: extensive local 
upregulation in adipose tissue but minimal systemic alterations. Endocrinology, 
2007. 
71. Kim TK, St John LS, Wieder ED, Khalili J, Ma Q, and Komanduri KV. 
Human Late Memory CD8+ T Cells Have a Distinct Cytokine Signature 
Characterized by CC Chemokine Production without IL-2 Production. J Immunol, 
2009. 
 130 
72. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, 
Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, 
Bluher M, Unger T, Wolf AM, Knippschild U, Hombach V, and Marx N. T-
lymphocyte Infiltration in Visceral Adipose Tissue. A Primary Event in Adipose 
Tissue Inflammation and the Development of Obesity-Mediated Insulin 
Resistance. Arterioscler Thromb Vasc Biol, 2008. 
73. Kirk EA, Sagawa ZK, McDonald TO, O'Brien KD, and Heinecke JW. 
Macrophage chemoattractant protein-1 deficiency fails to restrain macrophage 
infiltration into adipose tissue. Diabetes 57: 1254-1261, 2008. 
74. Kirk EA, Sagawa ZK, McDonald TO, O'Brien KD, and Heinecke JW. 
Monocyte chemoattractant protein deficiency fails to restrain macrophage 
infiltration into adipose tissue [corrected]. Diabetes 57: 1254-1261, 2008. 
75. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, 
and Eckel RH. Clinical implications of obesity with specific focus on 
cardiovascular disease: a statement for professionals from the American Heart 
Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by 
the American College of Cardiology Foundation. Circulation 110: 2952-2967, 
2004. 
76. Knudson JD, Dincer UD, Zhang C, Swafford AN, Jr., Koshida R, 
Picchi A, Focardi M, Dick GM, and Tune JD. Leptin receptors are expressed in 
coronary arteries, and hyperleptinemia causes significant coronary endothelial 
dysfunction. Am J Physiol Heart Circ Physiol 289: H48-56, 2005. 
77. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, 
Poreba R, and Mazurek W. Chemokines and left ventricular function in patients 
with acute myocardial infarction. Eur J Intern Med 18: 288-294, 2007. 
78. Koenen TB, Tack CJ, Kroese JM, Hermus AR, Sweep FC, van der 
Laak J, Stalenhoef AF, de Graaf J, van Tits LJ, and Stienstra R. Pioglitazone 
treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin 
Endocrinol Metab 94: 4453-4457, 2009. 
79. Konturek SJ, Konturek JW, Pawlik T, and Brzozowski T. Brain-gut axis 
and its role in the control of food intake. J Physiol Pharmacol 55: 137-154, 2004. 
80. Kraaijeveld AO, de Jager SC, de Jager WJ, Prakken BJ, McColl SR, 
Haspels I, Putter H, van Berkel TJ, Nagelkerken L, Jukema JW, and Biessen 
EA. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 
(CCL18/PARC) are specific markers of refractory unstable angina pectoris and 
are transiently raised during severe ischemic symptoms. Circulation 116: 1931-
1941, 2007. 
 131 
81. Kuziel WA, Dawson TC, Quinones M, Garavito E, Chenaux G, Ahuja 
SS, Reddick RL, and Maeda N. CCR5 deficiency is not protective in the early 
stages of atherogenesis in apoE knockout mice. Atherosclerosis 167: 25-32, 
2003. 
82. Lara-Castro C and Garvey WT. Intracellular lipid accumulation in liver 
and muscle and the insulin resistance syndrome. Endocrinol Metab Clin North 
Am 37: 841-856, 2008. 
83. Lee FY, Li Y, Yang EK, Yang SQ, Lin HZ, Trush MA, Dannenberg AJ, 
and Diehl AM. Phenotypic abnormalities in macrophages from leptin-deficient, 
obese mice. flc386 276: C386-394., 1999. 
84. Lee YH, Nair S, Rousseau E, Allison DB, Page GP, Tataranni PA, 
Bogardus C, and Permana PA. Microarray profiling of isolated abdominal 
subcutaneous adipocytes from obese vs non-obese Pima Indians: increased 
expression of inflammation-related genes. Diabetologia 48: 1776-1783, 2005. 
85. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002. 
86. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, 
Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, 
Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, 
McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, 
Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, 
Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, and Hong Y. Heart disease 
and stroke statistics--2009 update: a report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: e21-
181, 2009. 
87. Lloyd CM, Phillips AR, Cooper GJ, and Dunbar PR. Three-colour 
fluorescence immunohistochemistry reveals the diversity of cells staining for 
macrophage markers in murine spleen and liver. J Immunol Methods 334: 70-81, 
2008. 
88. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein 
AS, Bulkley GB, Bao C, Noble PW, Lane MD, and Diehl AM. Leptin regulates 
proinflammatory immune responses. Faseb J 12: 57-65, 1998. 
89. Lumeng CN, DelProposto JB, Westcott DJ, and Saltiel AR. Phenotypic 
switching of adipose tissue macrophages with obesity is generated by 
spatiotemporal differences in macrophage subtypes. Diabetes 57: 3239-3246, 
2008. 
90. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, 
Kim S, Lallone R, Ranganathan S, and al. e. Leptin levels in human and 
 132 
rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced 
subjects. Nat Med 1: 1155-1161, 1995. 
91. Magni P, Liuzzi A, Ruscica M, Dozio E, Ferrario S, Bussi I, Minocci A, 
Castagna A, Motta M, and Savia G. Free and bound plasma leptin in normal 
weight and obese men and women: relationship with body composition, resting 
energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. 
Clin Endocrinol (Oxf) 62: 189-196, 2005. 
92. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, and Locati M. 
The chemokine system in diverse forms of macrophage activation and 
polarization. Trends Immunol 25: 677-686, 2004. 
93. Marais AD, Firth JC, and Blom DJ. Homozygous familial 
hypercholesterolemia and its management. Semin Vasc Med 4: 43-50, 2004. 
94. Mark AL, Correia ML, Rahmouni K, and Haynes WG. Selective leptin 
resistance: a new concept in leptin physiology with cardiovascular implications. J 
Hypertens 20: 1245-1250, 2002. 
95. Martin-Romero C and Sanchez-Margalet V. Human leptin activates 
PI3K and MAPK pathways in human peripheral blood mononuclear cells: 
possible role of Sam68. Cell Immunol 212: 83-91., 2001. 
96. Maurer M and von Stebut E. Macrophage inflammatory protein-1. Int J 
Biochem Cell Biol 36: 1882-1886, 2004. 
97. McGill HC, Jr., McMahan CA, Herderick EE, Zieske AW, Malcom GT, 
Tracy RE, and Strong JP. Obesity accelerates the progression of coronary 
atherosclerosis in young men. Circulation 105: 2712-2718, 2002. 
98. Menten P, Wuyts A, and Van Damme J. Macrophage inflammatory 
protein-1. Cytokine Growth Factor Rev 13: 455-481, 2002. 
99. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, and Koplan 
JP. The continuing epidemics of obesity and diabetes in the United States. Jama 
286: 1195-1200, 2001. 
100. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci 
M, and Cinti S. Dead adipocytes, detected as crown-like structures (CLS), are 
prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49: 1562-
1568, 2008. 
101. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci 
M, and Cinti S. Dead adipocytes, detected as crown-like structures (CLS), are 
prevalent in visceral fat depots of genetically obese mice. J Lipid Res, 2008. 
 133 
102. Murdolo G, Hammarstedt A, Sandqvist M, Schmelz M, Herder C, 
Smith U, and Jansson PA. Monocyte chemoattractant protein-1 in 
subcutaneous abdominal adipose tissue: characterization of interstitial 
concentration and regulation of gene expression by insulin. J Clin Endocrinol 
Metab 92: 2688-2695, 2007. 
103. Myers MG, Cowley MA, and Munzberg H. Mechanisms of leptin action 
and leptin resistance. Annu Rev Physiol 70: 537-556, 2008. 
104. Nara N, Nakayama Y, Okamoto S, Tamura H, Kiyono M, Muraoka M, 
Tanaka K, Taya C, Shitara H, Ishii R, Yonekawa H, Minokoshi Y, and Hara T. 
Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-
induced insulin resistance. J Biol Chem 282: 30794-30803, 2007. 
105. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, 
Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, and Nagai R. 
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue 
inflammation in obesity. Nat Med 15: 914-920, 2009. 
106. O'Rourke L, Yeaman SJ, and Shepherd PR. Insulin and leptin acutely 
regulate cholesterol ester metabolism in macrophages by novel signaling 
pathways. Diabetes 50: 955-961, 2001. 
107. Oda A, Taniguchi T, and Yokoyama M. Leptin stimulates rat aortic 
smooth muscle cell proliferation and migration. Kobe J Med Sci 47: 141-150, 
2001. 
108. Okamoto Y, Higashiyama H, Rong JX, McVey MJ, Kinoshita M, Asano 
S, and Hansen MK. Comparison of mitochondrial and macrophage content 
between subcutaneous and visceral fat in db/db mice. Exp Mol Pathol 83: 73-83, 
2007. 
109. Organization WH. Obesity and overweight. 
110. Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, Fujimoto A, 
Shionoiri F, Yahagi N, Kraemer FB, Tsutsumi O, and Yamada N. Targeted 
disruption of hormone-sensitive lipase results in male sterility and adipocyte 
hypertrophy, but not in obesity. Proc Natl Acad Sci U S A 97: 787-792, 2000. 
111. Paigen B, Morrow A, Holmes PA, Mitchell D, and Williams RA. 
Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68: 
231-240, 1987. 
112. Pang C, Gao Z, Yin J, Zhang J, Jia W, and Ye J. Macrophage Infiltration 
into Adipose Tissue May Promote Angiogenesis for Adipose Tissue Remodeling 
in Obesity. Am J Physiol Endocrinol Metab, 2008. 
 134 
113. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas 
SM, and Kremastinos DT. Serum profiles of C-C chemokines in acute 
myocardial infarction: possible implication in postinfarction left ventricular 
remodeling. J Interferon Cytokine Res 22: 223-229, 2002. 
114. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho 
SY, and Kim HS. Potential role of leptin in angiogenesis: leptin induces 
endothelial cell proliferation and expression of matrix metalloproteinases in vivo 
and in vitro. Exp Mol Med 33: 95-102, 2001. 
115. Paximadis M, Mohanlal N, Gray GE, Kuhn L, and Tiemessen CT. 
Identification of new variants within the two functional genes CCL3 and CCL3L 
encoding the CCL3 (MIP-1alpha) chemokine: implications for HIV-1 infection. Int 
J Immunogenet 36: 21-32, 2009. 
116. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone 
T, and Collins F. Effects of the obese gene product on body weight regulation in 
ob/ob mice. Science 269: 540-543, 1995. 
117. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, and Maeda N. 
Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene 
targeting in embryonic stem cells. Proc Natl Acad Sci U S A 89: 4471-4475, 
1992. 
118. Poglio S, Galvani S, Bour S, Andre M, Prunet-Marcassus B, Penicaud 
L, Casteilla L, and Cousin B. Adipose tissue sensitivity to radiation exposure. 
Am J Pathol 174: 44-53, 2009. 
119. Potteaux S, Combadiere C, Esposito B, Casanova S, Merval R, 
Ardouin P, Gao JL, Murphy PM, Tedgui A, and Mallat Z. Chemokine receptor 
CCR1 disruption in bone marrow cells enhances atherosclerotic lesion 
development and inflammation in mice. Mol Med 11: 16-20, 2005. 
120. Potteaux S, Combadiere C, Esposito B, Lecureuil C, Ait-Oufella H, 
Merval R, Ardouin P, Tedgui A, and Mallat Z. Role of bone marrow-derived 
CC-chemokine receptor 5 in the development of atherosclerosis of low-density 
lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 26: 1858-
1863, 2006. 
121. Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, 
Willmon O, Kulkarni H, Reddick RL, Fernandes G, Kuziel WA, Ahuja SK, 
and Ahuja SS. CC chemokine receptor 5 influences late-stage atherosclerosis. 
Atherosclerosis 195: e92-103, 2007. 
122. Ramos CD, Canetti C, Souto JT, Silva JS, Hogaboam CM, Ferreira 
SH, and Cunha FQ. MIP-1alpha[CCL3] acting on the CCR1 receptor mediates 
 135 
neutrophil migration in immune inflammation via sequential release of TNF-alpha 
and LTB4. J Leukoc Biol 78: 167-177, 2005. 
123. Ramos CD, Fernandes KS, Canetti C, Teixeira MM, Silva JS, and 
Cunha FQ. Neutrophil recruitment in immunized mice depends on MIP-2 
inducing the sequential release of MIP-1alpha, TNF-alpha and LTB(4). Eur J 
Immunol 36: 2025-2034, 2006. 
124. Rausch ME, Weisberg S, Vardhana P, and Tortoriello DV. Obesity in 
C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell 
infiltration. Int J Obes (Lond) 32: 451-463, 2008. 
125. Reichel CA, Rehberg M, Lerchenberger M, Berberich N, Bihari P, 
Khandoga AG, Zahler S, and Krombach F. Ccl2 and Ccl3 mediate neutrophil 
recruitment via induction of protein synthesis and generation of lipid mediators. 
Arterioscler Thromb Vasc Biol 29: 1787-1793, 2009. 
126. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader 
DJ, and Kimmel SE. Plasma leptin levels are associated with coronary 
atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 89: 3872-3878, 2004. 
127. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, 
Colditz GA, and Willett WC. Body size and fat distribution as predictors of 
coronary heart disease among middle-aged and older US men. Am J Epidemiol 
141: 1117-1127, 1995. 
128. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, and Dahinden 
CA. RANTES and macrophage inflammatory protein 1 alpha induce the 
migration and activation of normal human eosinophil granulocytes. J Exp Med 
176: 1489-1495, 1992. 
129. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, 
Najib S, and Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood 
mononuclear cells: mechanisms of action. Clin Exp Immunol 133: 11-19, 2003. 
130. Santos-Alvarez J, Goberna R, and Sanchez-Margalet V. Human leptin 
stimulates proliferation and activation of human circulating monocytes. Cell 
Immunol 194: 6-11, 1999. 
131. Saraswathi V, Gao L, Morrow JD, Chait A, Niswender KD, and Hasty 
AH. Fish oil increases cholesterol storage in white adipose tissue with 
concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in 
mice. J Nutr 137: 1776-1782, 2007. 
 136 
132. Saraswathi V and Hasty AH. The role of lipolysis in mediating the 
proinflammatory effects of very low density lipoproteins in mouse peritoneal 
macrophages. J Lipid Res 47: 1406-1415, 2006. 
133. Satriano J. Arginine pathways and the inflammatory response: 
interregulation of nitric oxide and polyamines: review article. Amino Acids 26: 
321-329, 2004. 
134. Schall TJ, Bacon K, Camp RD, Kaspari JW, and Goeddel DV. Human 
macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta 
chemokines attract distinct populations of lymphocytes. J Exp Med 177: 1821-
1826, 1993. 
135. Schenk S, Saberi M, and Olefsky JM. Insulin sensitivity: modulation by 
nutrients and inflammation. J Clin Invest 118: 2992-3002, 2008. 
136. Sears DD, Hsiao G, Hsiao A, Yu JG, Courtney CH, Ofrecio JM, 
Chapman J, and Subramaniam S. Mechanisms of human insulin resistance 
and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci U S A 
106: 18745-18750, 2009. 
137. Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, and 
Yki-Jarvinen H. Adipose tissue inflammation and liver fat in patients with highly 
active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol 
Metab 295: E85-91, 2008. 
138. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, 
Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, 
Polverini PJ, and Flores-Riveros JR. Biological action of leptin as an 
angiogenic factor. Science 281: 1683-1686, 1998. 
139. Soderberg S, Stegmayr B, Ahlbeck-Glader C, Slunga-Birgander L, 
Ahren B, and Olsson T. High leptin levels are associated with stroke. 
Cerebrovasc Dis 15: 63-69, 2003. 
140. Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW, 2nd, DeFuria J, Jick 
Z, Greenberg AS, and Obin MS. Adipocyte death, adipose tissue remodeling, 
and obesity complications. Diabetes 56: 2910-2918, 2007. 
141. Suganami T, Nishida J, and Ogawa Y. A paracrine loop between 
adipocytes and macrophages aggravates inflammatory changes: role of free fatty 
acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 25: 2062-
2068, 2005. 
 137 
142. Surmi BK, Atkinson RD, Gruen ML, Coenen KR, and Hasty AH. The 
role of macrophage leptin receptor in aortic root lesion formation. Am J Physiol 
Endocrinol Metab 294: E488-495, 2008. 
143. Surmi BK and Hasty AH. Macrophage infiltration into adipose tissue: 
initiation, propagation and remodeling. Future Lipidol 3: 545-556, 2008. 
144. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, 
Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty 
A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, and Tepper RI. 
Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-
1271, 1995. 
145. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, and Kelvin DJ. 
Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 
alpha and MIP-1 beta. Science 260: 355-358, 1993. 
146. Taub DD, Sayers TJ, Carter CR, and Ortaldo JR. Alpha and beta 
chemokines induce NK cell migration and enhance NK-mediated cytolysis. J 
Immunol 155: 3877-3888, 1995. 
147. Trevaskis JL, Gawronska-Kozak B, Sutton GM, McNeil M, Stephens 
JM, Smith SR, and Butler AA. Role of adiponectin and inflammation in insulin 
resistance of mc3r and mc4r knockout mice. Obesity (Silver Spring) 15: 2664-
2672, 2007. 
148. Trifilo MJ, Bergmann CC, Kuziel WA, and Lane TE. CC chemokine 
ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following 
viral infection. J Virol 77: 4004-4014, 2003. 
149. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, 
Mack M, and Charo IF. Critical roles for CCR2 and MCP-3 in monocyte 
mobilization from bone marrow and recruitment to inflammatory sites. J Clin 
Invest 117: 902-909, 2007. 
150. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, and Baggiolini M. 
Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 
alpha and MIP-1 beta on human monocytes. Eur J Immunol 25: 64-68, 1995. 
151. Van Gaal LF, Mertens IL, and De Block CE. Mechanisms linking obesity 
with cardiovascular disease. Nature 444: 875-880, 2006. 
152. Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, Gentile 
MT, Fratta L, Trimarco V, Trimarco B, and Lembo G. Leptin effect on 
endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase 
phosphorylation pathway. Diabetes 51: 168-173, 2002. 
 138 
153. Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, and Lijnen 
HR. Modulation of angiogenesis during adipose tissue development in murine 
models of obesity. Endocrinology 146: 4545-4554, 2005. 
154. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, 
and Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of 
Scotland coronary prevention study (WOSCOPS). Circulation 104: 3052-3056, 
2001. 
155. Wang B, Wood I, and Trayhurn P. Hypoxia induces leptin gene 
expression and secretion in human preadipocytes: differential effects of hypoxia 
on adipokine expression by preadipocytes. J Endocrinol, 2008. 
156. Wang B, Wood IS, and Trayhurn P. Dysregulation of the expression and 
secretion of inflammation-related adipokines by hypoxia in human adipocytes. 
Pflugers Arch 455: 479-492, 2007. 
157. Weber C, Zernecke A, and Libby P. The multifaceted contributions of 
leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev 
Immunol 8: 802-815, 2008. 
158. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, 
Charo I, Leibel RL, and Ferrante AW, Jr. CCR2 modulates inflammatory and 
metabolic effects of high-fat feeding. J Clin Invest 116: 115-124, 2006. 
159. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, and 
Ferrante AW, Jr. Obesity is associated with macrophage accumulation in 
adipose tissue. J Clin Invest 112: 1796-1808, 2003. 
160. Westerbacka J, Corner A, Kolak M, Makkonen J, Turpeinen U, 
Hamsten A, Fisher RM, and Yki-Jarvinen H. Insulin regulation of MCP-1 in 
human adipose tissue of obese and lean women. Am J Physiol Endocrinol Metab 
294: E841-845, 2008. 
161. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer 
FE, and Hennekens CH. Weight, weight change, and coronary heart disease in 
women. Risk within the 'normal' weight range. Jama 273: 461-465, 1995. 
162. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, 
Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, 
Winer D, and Dosch HM. Normalization of obesity-associated insulin resistance 
through immunotherapy. Nat Med 15: 921-929, 2009. 
163. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann 
D, Kerksiek A, van Kruchten R, Maeda N, Staels B, van Bilsen M, Shiri-
Sverdlov R, and Hofker MH. Dietary cholesterol, rather than liver steatosis, 
 139 
leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic 
steatohepatitis. Hepatology 48: 474-486, 2008. 
164. Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, Sweeney 
JF, Peterson LE, Chan L, Smith CW, and Ballantyne CM. T-cell accumulation 
and regulated on activation, normal T cell expressed and secreted upregulation 
in adipose tissue in obesity. Circulation 115: 1029-1038, 2007. 
165. Wu YP and Proia RL. Deletion of macrophage-inflammatory protein 1 
alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci U 
S A 101: 8425-8430, 2004. 
166. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, 
Ross JS, Tartaglia LA, and Chen H. Chronic inflammation in fat plays a crucial 
role in the development of obesity-related insulin resistance. J Clin Invest 112: 
1821-1830, 2003. 
167. Ye J, Gao Z, Yin J, and He Q. Hypoxia is a potential risk factor for chronic 
inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary 
obese mice. Am J Physiol Endocrinol Metab 293: E1118-1128, 2007. 
168. Yu R, Kim CS, Kwon BS, and Kawada T. Mesenteric adipose tissue-
derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue 
macrophage migration and activation in obese mice. Obesity (Silver Spring) 14: 
1353-1362, 2006. 
169. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, and Weber C. 
Deficiency in CCR5 but not CCR1 protects against neointima formation in 
atherosclerosis-prone mice: involvement of IL-10. Blood 107: 4240-4243, 2006. 
170. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, 
Zlabinger GJ, and Stulnig TM. Human adipose tissue macrophages are of an 
anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator 
production. Int J Obes (Lond) 31: 1420-1428, 2007. 
171. Zhang SH, Reddick RL, Piedrahita JA, and Maeda N. Spontaneous 
hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. 
Science 258: 468-471, 1992. 
172. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, and Friedman 
JM. Positional cloning of the mouse obese gene and its human homologue. 
Nature 372: 425-432, 1994. 
173. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, John N, 
Schmidt S, Spanbroek R, Lotzer K, Huang L, Cui J, Rader DJ, Evans JF, 
Habenicht AJ, and Funk CD. The 5-lipoxygenase pathway promotes 
 140 
pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10: 966-
973, 2004. 
174. Zimmermann R, Lass A, Haemmerle G, and Zechner R. Fate of fat: the 
role of adipose triglyceride lipase in lipolysis. Biochim Biophys Acta 1791: 494-
500, 2009. 
 
 
